HRP20120735T1 - Derivati fosfonske kiseline i njihova uporaba kao antagonista p2y12 receptora - Google Patents
Derivati fosfonske kiseline i njihova uporaba kao antagonista p2y12 receptora Download PDFInfo
- Publication number
- HRP20120735T1 HRP20120735T1 HRP20120735AT HRP20120735T HRP20120735T1 HR P20120735 T1 HRP20120735 T1 HR P20120735T1 HR P20120735A T HRP20120735A T HR P20120735AT HR P20120735 T HRP20120735 T HR P20120735T HR P20120735 T1 HRP20120735 T1 HR P20120735T1
- Authority
- HR
- Croatia
- Prior art keywords
- phenyl
- carbonyl
- amino
- piperazine
- carboxylic acid
- Prior art date
Links
- 229940127424 P2Y12 Receptor Antagonists Drugs 0.000 title 1
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical compound OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 33
- 229910052757 nitrogen Inorganic materials 0.000 claims 22
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 claims 17
- 150000003839 salts Chemical class 0.000 claims 16
- 125000000217 alkyl group Chemical group 0.000 claims 10
- 125000000623 heterocyclic group Chemical group 0.000 claims 8
- 229910052739 hydrogen Inorganic materials 0.000 claims 8
- 239000001257 hydrogen Substances 0.000 claims 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 8
- -1 hydroxy, hydroxymethyl Chemical group 0.000 claims 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 5
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 4
- 125000000753 cycloalkyl group Chemical group 0.000 claims 4
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 4
- 101100244083 Arabidopsis thaliana PKL gene Proteins 0.000 claims 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 3
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims 3
- 125000003545 alkoxy group Chemical group 0.000 claims 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 3
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 3
- XSEQYYOXBPJMIR-IGKIAQTJSA-N [4-[(2s)-3-(4-ethoxycarbonylpiperazin-1-yl)-2-[[6-[(3s)-3-methoxypyrrolidin-1-yl]-2-phenylpyrimidine-4-carbonyl]amino]-3-oxopropyl]phenyl]phosphonic acid Chemical compound C1CN(C(=O)OCC)CCN1C(=O)[C@@H](NC(=O)C=1N=C(N=C(C=1)N1C[C@H](CC1)OC)C=1C=CC=CC=1)CC1=CC=C(P(O)(O)=O)C=C1 XSEQYYOXBPJMIR-IGKIAQTJSA-N 0.000 claims 2
- 125000005078 alkoxycarbonylalkyl group Chemical group 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- 125000004181 carboxyalkyl group Chemical group 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 208000019553 vascular disease Diseases 0.000 claims 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 1
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 1
- GMFFAGTXZZGGNX-FQEVSTJZSA-N 3-[[6-[[(2r)-1-(4-butoxycarbonylpiperazin-1-yl)-1-oxo-3-phosphonopropan-2-yl]carbamoyl]-2-phenylpyrimidin-4-yl]amino]propanoic acid Chemical compound C1CN(C(=O)OCCCC)CCN1C(=O)[C@H](CP(O)(O)=O)NC(=O)C1=CC(NCCC(O)=O)=NC(C=2C=CC=CC=2)=N1 GMFFAGTXZZGGNX-FQEVSTJZSA-N 0.000 claims 1
- XXWMATPZZRMUPC-DEFVIDAGSA-N 4-[(2R)-2-[[6-[(3S)-3-methoxypyrrolidin-1-yl]-2-phenylpyrimidine-4-carbonyl]amino]-3-(2-oxo-1,4-dihydro-3,1,2lambda5-benzoxazaphosphinin-2-yl)propanoyl]piperazine-1-carboxylic acid Chemical compound CO[C@@H]1CN(CC1)C1=CC(=NC(=N1)C1=CC=CC=C1)C(=O)N[C@H](C(=O)N1CCN(CC1)C(=O)O)CP1(OCC2=C(N1)C=CC=C2)=O XXWMATPZZRMUPC-DEFVIDAGSA-N 0.000 claims 1
- PJKZAFHPZUROJB-GMAHTHKFSA-N 4-[(2R)-3-[(5-tert-butyl-2-oxo-1,3-dioxol-4-yl)methoxy-hydroxyphosphoryl]-2-[[6-[(3S)-3-methoxypyrrolidin-1-yl]-2-phenylpyrimidine-4-carbonyl]amino]propanoyl]piperazine-1-carboxylic acid Chemical compound CO[C@H]1CCN(C1)C1=NC(=NC(=C1)C(=O)N[C@@H](CP(O)(=O)OCC1=C(OC(=O)O1)C(C)(C)C)C(=O)N1CCN(CC1)C(O)=O)C1=CC=CC=C1 PJKZAFHPZUROJB-GMAHTHKFSA-N 0.000 claims 1
- 101100495911 Arabidopsis thaliana CHR10 gene Proteins 0.000 claims 1
- NBIQFKPKGYYHGL-BDYUSTAISA-N [(2R)-3-(4-butoxycarbonylpiperazin-1-yl)-2-[[6-[(3S)-3-methoxypyrrolidin-1-yl]-2-phenylpyrimidine-4-carbonyl]amino]-3-oxopropylidene]-(1,3-diethoxy-1,3-dioxopropan-2-yl)oxy-oxidophosphanium Chemical compound C1CN(C(=O)OCCCC)CCN1C(=O)[C@H](C=P(=O)OC(C(=O)OCC)C(=O)OCC)NC(=O)C1=CC(N2C[C@H](CC2)OC)=NC(C=2C=CC=CC=2)=N1 NBIQFKPKGYYHGL-BDYUSTAISA-N 0.000 claims 1
- IGTVOTZFNVCPIU-YTMVLYRLSA-N [(2R)-3-(4-butoxycarbonylpiperazin-1-yl)-2-[[6-[(3S)-3-methoxypyrrolidin-1-yl]-2-phenylpyrimidine-4-carbonyl]amino]-3-oxopropylidene]-[di(butanoyloxy)methoxy]-oxidophosphanium Chemical compound C1CN(C(=O)OCCCC)CCN1C(=O)[C@H](C=P(=O)OC(OC(=O)CCC)OC(=O)CCC)NC(=O)C1=CC(N2C[C@H](CC2)OC)=NC(C=2C=CC=CC=2)=N1 IGTVOTZFNVCPIU-YTMVLYRLSA-N 0.000 claims 1
- SKPOMRGCFYKOJR-BDYUSTAISA-N [(2R)-3-(4-butoxycarbonylpiperazin-1-yl)-2-[[6-[(3S)-3-methoxypyrrolidin-1-yl]-2-phenylpyrimidine-4-carbonyl]amino]-3-oxopropylidene]-[di(propanoyloxy)methoxy]-oxidophosphanium Chemical compound C1CN(C(=O)OCCCC)CCN1C(=O)[C@H](C=P(=O)OC(OC(=O)CC)OC(=O)CC)NC(=O)C1=CC(N2C[C@H](CC2)OC)=NC(C=2C=CC=CC=2)=N1 SKPOMRGCFYKOJR-BDYUSTAISA-N 0.000 claims 1
- RQNFSCXJDNQLNR-DEOSSOPVSA-N [(2r)-2-[(6-anilino-2-phenylpyrimidine-4-carbonyl)amino]-3-(4-butoxycarbonylpiperazin-1-yl)-3-oxopropyl]phosphonic acid Chemical compound C1CN(C(=O)OCCCC)CCN1C(=O)[C@H](CP(O)(O)=O)NC(=O)C1=CC(NC=2C=CC=CC=2)=NC(C=2C=CC=CC=2)=N1 RQNFSCXJDNQLNR-DEOSSOPVSA-N 0.000 claims 1
- SNQPOAHBMGFJJT-NRFANRHFSA-N [(2r)-2-[(6-cyclopentyloxy-2-phenylpyrimidine-4-carbonyl)amino]-3-(4-ethoxycarbonylpiperazin-1-yl)-3-oxopropyl]phosphonic acid Chemical compound C1CN(C(=O)OCC)CCN1C(=O)[C@H](CP(O)(O)=O)NC(=O)C1=CC(OC2CCCC2)=NC(C=2C=CC=CC=2)=N1 SNQPOAHBMGFJJT-NRFANRHFSA-N 0.000 claims 1
- KZNHRUSKMBYQFQ-VWLOTQADSA-N [(2r)-2-[[6-(benzylamino)-2-phenylpyrimidine-4-carbonyl]amino]-3-(4-butoxycarbonylpiperazin-1-yl)-3-oxopropyl]phosphonic acid Chemical compound C1CN(C(=O)OCCCC)CCN1C(=O)[C@H](CP(O)(O)=O)NC(=O)C1=CC(NCC=2C=CC=CC=2)=NC(C=2C=CC=CC=2)=N1 KZNHRUSKMBYQFQ-VWLOTQADSA-N 0.000 claims 1
- ZKGGNIINLKGOAV-VWLOTQADSA-N [(2r)-3-(4-butoxycarbonylpiperazin-1-yl)-2-[(2,6-diphenylpyrimidine-4-carbonyl)amino]-3-oxopropyl]phosphonic acid Chemical compound C1CN(C(=O)OCCCC)CCN1C(=O)[C@H](CP(O)(O)=O)NC(=O)C1=CC(C=2C=CC=CC=2)=NC(C=2C=CC=CC=2)=N1 ZKGGNIINLKGOAV-VWLOTQADSA-N 0.000 claims 1
- IXKIZHKPVWLFEW-QHCPKHFHSA-N [(2r)-3-(4-butoxycarbonylpiperazin-1-yl)-2-[(6-butyl-2-phenylpyrimidine-4-carbonyl)amino]-3-oxopropyl]phosphonic acid Chemical compound C1CN(C(=O)OCCCC)CCN1C(=O)[C@H](CP(O)(O)=O)NC(=O)C1=CC(CCCC)=NC(C=2C=CC=CC=2)=N1 IXKIZHKPVWLFEW-QHCPKHFHSA-N 0.000 claims 1
- YWXHUXDIPMAKSJ-QFIPXVFZSA-N [(2r)-3-(4-butoxycarbonylpiperazin-1-yl)-2-[(6-cyclopropyl-2-phenylpyrimidine-4-carbonyl)amino]-3-oxopropyl]phosphonic acid Chemical compound C1CN(C(=O)OCCCC)CCN1C(=O)[C@H](CP(O)(O)=O)NC(=O)C1=CC(C2CC2)=NC(C=2C=CC=CC=2)=N1 YWXHUXDIPMAKSJ-QFIPXVFZSA-N 0.000 claims 1
- MLZWCFZUBDJDPU-IBGZPJMESA-N [(2r)-3-(4-butoxycarbonylpiperazin-1-yl)-2-[(6-methoxy-2-phenylpyrimidine-4-carbonyl)amino]-3-oxopropyl]phosphonic acid Chemical compound C1CN(C(=O)OCCCC)CCN1C(=O)[C@H](CP(O)(O)=O)NC(=O)C1=CC(OC)=NC(C=2C=CC=CC=2)=N1 MLZWCFZUBDJDPU-IBGZPJMESA-N 0.000 claims 1
- FYULDEVCQPUJCT-FQEVSTJZSA-N [(2r)-3-(4-butoxycarbonylpiperazin-1-yl)-2-[(6-methyl-2-phenylpyrimidine-4-carbonyl)amino]-3-oxopropyl]phosphonic acid Chemical compound C1CN(C(=O)OCCCC)CCN1C(=O)[C@H](CP(O)(O)=O)NC(=O)C1=CC(C)=NC(C=2C=CC=CC=2)=N1 FYULDEVCQPUJCT-FQEVSTJZSA-N 0.000 claims 1
- KYYQEBSLEMOPEO-QFIPXVFZSA-N [(2r)-3-(4-butoxycarbonylpiperazin-1-yl)-2-[(6-morpholin-4-yl-2-phenylpyrimidine-4-carbonyl)amino]-3-oxopropyl]phosphonic acid Chemical compound C1CN(C(=O)OCCCC)CCN1C(=O)[C@H](CP(O)(O)=O)NC(=O)C1=CC(N2CCOCC2)=NC(C=2C=CC=CC=2)=N1 KYYQEBSLEMOPEO-QFIPXVFZSA-N 0.000 claims 1
- ZXJZEJVFJBBIRW-FQEVSTJZSA-N [(2r)-3-(4-butoxycarbonylpiperazin-1-yl)-2-[[6-(2-hydroxyethoxy)-2-phenylpyrimidine-4-carbonyl]amino]-3-oxopropyl]phosphonic acid Chemical compound C1CN(C(=O)OCCCC)CCN1C(=O)[C@H](CP(O)(O)=O)NC(=O)C1=CC(OCCO)=NC(C=2C=CC=CC=2)=N1 ZXJZEJVFJBBIRW-FQEVSTJZSA-N 0.000 claims 1
- IXJZNZWOIJFYIW-FQEVSTJZSA-N [(2r)-3-(4-butoxycarbonylpiperazin-1-yl)-2-[[6-(2-hydroxyethylamino)-2-phenylpyrimidine-4-carbonyl]amino]-3-oxopropyl]phosphonic acid Chemical compound C1CN(C(=O)OCCCC)CCN1C(=O)[C@H](CP(O)(O)=O)NC(=O)C1=CC(NCCO)=NC(C=2C=CC=CC=2)=N1 IXJZNZWOIJFYIW-FQEVSTJZSA-N 0.000 claims 1
- YHBDUZGNVHRZIY-BVHINDKJSA-N [(2r)-3-(4-butoxycarbonylpiperazin-1-yl)-2-[[6-(3-hydroxybutyl)-2-phenylpyrimidine-4-carbonyl]amino]-3-oxopropyl]phosphonic acid Chemical compound C1CN(C(=O)OCCCC)CCN1C(=O)[C@H](CP(O)(O)=O)NC(=O)C1=CC(CCC(C)O)=NC(C=2C=CC=CC=2)=N1 YHBDUZGNVHRZIY-BVHINDKJSA-N 0.000 claims 1
- FSCKTWHZGDCVBZ-IAXKEJLGSA-N [(2r)-3-(4-butoxycarbonylpiperazin-1-yl)-2-[[6-(3-hydroxypyrrolidin-1-yl)-2-phenylpyrimidine-4-carbonyl]amino]-3-oxopropyl]phosphonic acid Chemical compound C1CN(C(=O)OCCCC)CCN1C(=O)[C@H](CP(O)(O)=O)NC(=O)C1=CC(N2CC(O)CC2)=NC(C=2C=CC=CC=2)=N1 FSCKTWHZGDCVBZ-IAXKEJLGSA-N 0.000 claims 1
- FVYNJWCPGKRIKW-QHCPKHFHSA-N [(2r)-3-(4-butoxycarbonylpiperazin-1-yl)-2-[[6-(3-methoxypropyl)-2-phenylpyrimidine-4-carbonyl]amino]-3-oxopropyl]phosphonic acid Chemical compound C1CN(C(=O)OCCCC)CCN1C(=O)[C@H](CP(O)(O)=O)NC(=O)C1=CC(CCCOC)=NC(C=2C=CC=CC=2)=N1 FVYNJWCPGKRIKW-QHCPKHFHSA-N 0.000 claims 1
- CULGTOBNCGSYGM-SANMLTNESA-N [(2r)-3-(4-butoxycarbonylpiperazin-1-yl)-2-[[6-(4-methoxyphenyl)-2-phenylpyrimidine-4-carbonyl]amino]-3-oxopropyl]phosphonic acid Chemical compound C1CN(C(=O)OCCCC)CCN1C(=O)[C@H](CP(O)(O)=O)NC(=O)C1=CC(C=2C=CC(OC)=CC=2)=NC(C=2C=CC=CC=2)=N1 CULGTOBNCGSYGM-SANMLTNESA-N 0.000 claims 1
- ZJTCYSPTLFEVPH-QHCPKHFHSA-N [(2r)-3-(4-butoxycarbonylpiperazin-1-yl)-2-[[6-(4-methylpiperazin-1-yl)-2-phenylpyrimidine-4-carbonyl]amino]-3-oxopropyl]phosphonic acid Chemical compound C1CN(C(=O)OCCCC)CCN1C(=O)[C@H](CP(O)(O)=O)NC(=O)C1=CC(N2CCN(C)CC2)=NC(C=2C=CC=CC=2)=N1 ZJTCYSPTLFEVPH-QHCPKHFHSA-N 0.000 claims 1
- SXMNWPGLIKJQMU-NRFANRHFSA-N [(2r)-3-(4-butoxycarbonylpiperazin-1-yl)-2-[[6-(cyclopropylamino)-2-phenylpyrimidine-4-carbonyl]amino]-3-oxopropyl]phosphonic acid Chemical compound C1CN(C(=O)OCCCC)CCN1C(=O)[C@H](CP(O)(O)=O)NC(=O)C1=CC(NC2CC2)=NC(C=2C=CC=CC=2)=N1 SXMNWPGLIKJQMU-NRFANRHFSA-N 0.000 claims 1
- HBZCFGLKDYWRMJ-FQEVSTJZSA-N [(2r)-3-(4-butoxycarbonylpiperazin-1-yl)-2-[[6-(dimethylamino)-2-phenylpyrimidine-4-carbonyl]amino]-3-oxopropyl]phosphonic acid Chemical compound C1CN(C(=O)OCCCC)CCN1C(=O)[C@H](CP(O)(O)=O)NC(=O)C1=CC(N(C)C)=NC(C=2C=CC=CC=2)=N1 HBZCFGLKDYWRMJ-FQEVSTJZSA-N 0.000 claims 1
- VKZHGROLYAEBLP-FQEVSTJZSA-N [(2r)-3-(4-butoxycarbonylpiperazin-1-yl)-2-[[6-(ethylamino)-2-phenylpyrimidine-4-carbonyl]amino]-3-oxopropyl]phosphonic acid Chemical compound C1CN(C(=O)OCCCC)CCN1C(=O)[C@H](CP(O)(O)=O)NC(=O)C1=CC(NCC)=NC(C=2C=CC=CC=2)=N1 VKZHGROLYAEBLP-FQEVSTJZSA-N 0.000 claims 1
- LLSQIMQDQNIQTO-IBGZPJMESA-N [(2r)-3-(4-butoxycarbonylpiperazin-1-yl)-2-[[6-(methylamino)-2-phenylpyrimidine-4-carbonyl]amino]-3-oxopropyl]phosphonic acid Chemical compound C1CN(C(=O)OCCCC)CCN1C(=O)[C@H](CP(O)(O)=O)NC(=O)C1=CC(NC)=NC(C=2C=CC=CC=2)=N1 LLSQIMQDQNIQTO-IBGZPJMESA-N 0.000 claims 1
- HUHFJSXWVHBZRF-QTEQDKRBSA-N [(2r)-3-(4-butoxycarbonylpiperazin-1-yl)-2-[[6-[(1s,2s)-2-(hydroxymethyl)cyclopropyl]-2-phenylpyrimidine-4-carbonyl]amino]-3-oxopropyl]phosphonic acid Chemical compound C1CN(C(=O)OCCCC)CCN1C(=O)[C@H](CP(O)(O)=O)NC(=O)C1=CC([C@@H]2[C@H](C2)CO)=NC(C=2C=CC=CC=2)=N1 HUHFJSXWVHBZRF-QTEQDKRBSA-N 0.000 claims 1
- FAIKKQYAHATSDJ-DPLHUUCSSA-N [(2r)-3-(4-butoxycarbonylpiperazin-1-yl)-2-[[6-[(1s,2s)-2-(methoxymethyl)cyclopropyl]-2-phenylpyrimidine-4-carbonyl]amino]-3-oxopropyl]phosphonic acid Chemical compound C1CN(C(=O)OCCCC)CCN1C(=O)[C@H](CP(O)(O)=O)NC(=O)C1=CC([C@@H]2[C@H](C2)COC)=NC(C=2C=CC=CC=2)=N1 FAIKKQYAHATSDJ-DPLHUUCSSA-N 0.000 claims 1
- GSIXQFXJWHDKOU-QFIPXVFZSA-N [(2r)-3-(4-butoxycarbonylpiperazin-1-yl)-2-[[6-[(3-ethoxy-3-oxopropyl)amino]-2-phenylpyrimidine-4-carbonyl]amino]-3-oxopropyl]phosphonic acid Chemical compound C1CN(C(=O)OCCCC)CCN1C(=O)[C@H](CP(O)(O)=O)NC(=O)C1=CC(NCCC(=O)OCC)=NC(C=2C=CC=CC=2)=N1 GSIXQFXJWHDKOU-QFIPXVFZSA-N 0.000 claims 1
- QKOQYBRPAUUXCX-GITCGBDTSA-N [(2r)-3-(4-butoxycarbonylpiperazin-1-yl)-2-[[6-[2-(hydroxymethyl)piperidin-1-yl]-2-phenylpyrimidine-4-carbonyl]amino]-3-oxopropyl]phosphonic acid Chemical compound C1CN(C(=O)OCCCC)CCN1C(=O)[C@H](CP(O)(O)=O)NC(=O)C1=CC(N2C(CCCC2)CO)=NC(C=2C=CC=CC=2)=N1 QKOQYBRPAUUXCX-GITCGBDTSA-N 0.000 claims 1
- AIEKQADKDJTUNV-QFIPXVFZSA-N [(2r)-3-(4-butoxycarbonylpiperazin-1-yl)-2-[[6-[2-methoxyethyl(methyl)amino]-2-phenylpyrimidine-4-carbonyl]amino]-3-oxopropyl]phosphonic acid Chemical compound C1CN(C(=O)OCCCC)CCN1C(=O)[C@H](CP(O)(O)=O)NC(=O)C1=CC(N(C)CCOC)=NC(C=2C=CC=CC=2)=N1 AIEKQADKDJTUNV-QFIPXVFZSA-N 0.000 claims 1
- LNTMATIVLLGIGK-QHCPKHFHSA-N [(2r)-3-(4-butoxycarbonylpiperazin-1-yl)-2-[[6-[3-(methoxymethyl)azetidin-1-yl]-2-phenylpyrimidine-4-carbonyl]amino]-3-oxopropyl]phosphonic acid Chemical compound C1CN(C(=O)OCCCC)CCN1C(=O)[C@H](CP(O)(O)=O)NC(=O)C1=CC(N2CC(COC)C2)=NC(C=2C=CC=CC=2)=N1 LNTMATIVLLGIGK-QHCPKHFHSA-N 0.000 claims 1
- WQCWUBJLTUBDLU-QFIPXVFZSA-N [(2r)-3-(4-butoxycarbonylpiperazin-1-yl)-3-oxo-2-[(2-phenyl-6-propan-2-ylpyrimidine-4-carbonyl)amino]propyl]phosphonic acid Chemical compound C1CN(C(=O)OCCCC)CCN1C(=O)[C@H](CP(O)(O)=O)NC(=O)C1=CC(C(C)C)=NC(C=2C=CC=CC=2)=N1 WQCWUBJLTUBDLU-QFIPXVFZSA-N 0.000 claims 1
- BUCCRPCFXJLMSA-QHCPKHFHSA-N [(2r)-3-(4-butoxycarbonylpiperazin-1-yl)-3-oxo-2-[(2-phenyl-6-thiophen-3-ylpyrimidine-4-carbonyl)amino]propyl]phosphonic acid Chemical compound C1CN(C(=O)OCCCC)CCN1C(=O)[C@H](CP(O)(O)=O)NC(=O)C1=CC(C2=CSC=C2)=NC(C=2C=CC=CC=2)=N1 BUCCRPCFXJLMSA-QHCPKHFHSA-N 0.000 claims 1
- BBBRAUDIJZWUDG-NRFANRHFSA-N [(2r)-3-(4-butoxycarbonylpiperazin-1-yl)-3-oxo-2-[[2-phenyl-6-(propan-2-ylamino)pyrimidine-4-carbonyl]amino]propyl]phosphonic acid Chemical compound C1CN(C(=O)OCCCC)CCN1C(=O)[C@H](CP(O)(O)=O)NC(=O)C1=CC(NC(C)C)=NC(C=2C=CC=CC=2)=N1 BBBRAUDIJZWUDG-NRFANRHFSA-N 0.000 claims 1
- WMSMXWMDABUTGW-UNMCSNQZSA-N [(2r)-3-(4-butoxycarbonylpiperazin-1-yl)-3-oxo-2-[[6-[(3s)-oxolan-3-yl]oxy-2-phenylpyrimidine-4-carbonyl]amino]propyl]phosphonic acid Chemical compound C1CN(C(=O)OCCCC)CCN1C(=O)[C@H](CP(O)(O)=O)NC(=O)C1=CC(O[C@@H]2COCC2)=NC(C=2C=CC=CC=2)=N1 WMSMXWMDABUTGW-UNMCSNQZSA-N 0.000 claims 1
- OPBNRDWVVSLBBI-IRLDBZIGSA-N [(2r)-3-(4-butoxycarbonylpiperazin-1-yl)-3-oxo-2-[[6-[[(3r)-oxolan-3-yl]amino]-2-phenylpyrimidine-4-carbonyl]amino]propyl]phosphonic acid Chemical compound C1CN(C(=O)OCCCC)CCN1C(=O)[C@H](CP(O)(O)=O)NC(=O)C1=CC(N[C@H]2COCC2)=NC(C=2C=CC=CC=2)=N1 OPBNRDWVVSLBBI-IRLDBZIGSA-N 0.000 claims 1
- OGLXBNIASRSWFQ-KAOUJKNGSA-N [(2r)-3-(4-ethoxycarbonyl-3-methylpiperazin-1-yl)-2-[[6-[(3s)-3-methoxypyrrolidin-1-yl]-2-phenylpyrimidine-4-carbonyl]amino]-3-oxopropyl]phosphonic acid Chemical compound C1C(C)N(C(=O)OCC)CCN1C(=O)[C@H](CP(O)(O)=O)NC(=O)C1=CC(N2C[C@H](CC2)OC)=NC(C=2C=CC=CC=2)=N1 OGLXBNIASRSWFQ-KAOUJKNGSA-N 0.000 claims 1
- AKSRFSBIBZSANT-FPOVZHCZSA-N [(2r)-3-(4-ethoxycarbonylpiperazin-1-yl)-2-[[6-[(3s)-3-methoxypyrrolidin-1-yl]-2-phenylpyrimidine-4-carbonyl]amino]-3-oxopropyl]phosphonic acid Chemical compound C1CN(C(=O)OCC)CCN1C(=O)[C@H](CP(O)(O)=O)NC(=O)C1=CC(N2C[C@H](CC2)OC)=NC(C=2C=CC=CC=2)=N1 AKSRFSBIBZSANT-FPOVZHCZSA-N 0.000 claims 1
- FYXHWMQPCJOJCH-JTHBVZDNSA-N [(2s)-3-(4-butoxycarbonylpiperazin-1-yl)-2-[[6-[(3s)-3-methoxypyrrolidin-1-yl]-2-phenylpyrimidine-4-carbonyl]amino]-3-oxopropyl]phosphonic acid Chemical compound C1CN(C(=O)OCCCC)CCN1C(=O)[C@@H](CP(O)(O)=O)NC(=O)C1=CC(N2C[C@H](CC2)OC)=NC(C=2C=CC=CC=2)=N1 FYXHWMQPCJOJCH-JTHBVZDNSA-N 0.000 claims 1
- AKSRFSBIBZSANT-PZJWPPBQSA-N [(2s)-3-(4-ethoxycarbonylpiperazin-1-yl)-2-[[6-[(3s)-3-methoxypyrrolidin-1-yl]-2-phenylpyrimidine-4-carbonyl]amino]-3-oxopropyl]phosphonic acid Chemical compound C1CN(C(=O)OCC)CCN1C(=O)[C@@H](CP(O)(O)=O)NC(=O)C1=CC(N2C[C@H](CC2)OC)=NC(C=2C=CC=CC=2)=N1 AKSRFSBIBZSANT-PZJWPPBQSA-N 0.000 claims 1
- CFEYHNMCRFLPRJ-XZOQPEGZSA-N [(3r)-4-(4-butoxycarbonylpiperazin-1-yl)-3-[[6-[(3s)-3-methoxypyrrolidin-1-yl]-2-phenylpyrimidine-4-carbonyl]amino]-4-oxobutyl]phosphonic acid Chemical compound C1CN(C(=O)OCCCC)CCN1C(=O)[C@@H](CCP(O)(O)=O)NC(=O)C1=CC(N2C[C@H](CC2)OC)=NC(C=2C=CC=CC=2)=N1 CFEYHNMCRFLPRJ-XZOQPEGZSA-N 0.000 claims 1
- IVFUOMFADLXNHN-LEWJYISDSA-N [(3r)-4-(4-ethoxycarbonylpiperazin-1-yl)-3-[[6-[(3s)-3-methoxypyrrolidin-1-yl]-2-phenylpyrimidine-4-carbonyl]amino]-4-oxobutyl]phosphonic acid Chemical compound C1CN(C(=O)OCC)CCN1C(=O)[C@@H](CCP(O)(O)=O)NC(=O)C1=CC(N2C[C@H](CC2)OC)=NC(C=2C=CC=CC=2)=N1 IVFUOMFADLXNHN-LEWJYISDSA-N 0.000 claims 1
- MKPGWNOPRQYPPA-QFIPXVFZSA-N [(3s)-4-(4-butoxycarbonylpiperazin-1-yl)-3-[(6-morpholin-4-yl-2-phenylpyrimidine-4-carbonyl)amino]-4-oxobutyl]phosphonic acid Chemical compound C1CN(C(=O)OCCCC)CCN1C(=O)[C@H](CCP(O)(O)=O)NC(=O)C1=CC(N2CCOCC2)=NC(C=2C=CC=CC=2)=N1 MKPGWNOPRQYPPA-QFIPXVFZSA-N 0.000 claims 1
- PKAMBGIIZWSYPM-REWPJTCUSA-N [(3s)-4-(4-butoxycarbonylpiperazin-1-yl)-3-[[2-(2-fluorophenyl)-6-[(3s)-3-methoxypyrrolidin-1-yl]pyrimidine-4-carbonyl]amino]-4-oxobutyl]phosphonic acid Chemical compound C1CN(C(=O)OCCCC)CCN1C(=O)[C@H](CCP(O)(O)=O)NC(=O)C1=CC(N2C[C@H](CC2)OC)=NC(C=2C(=CC=CC=2)F)=N1 PKAMBGIIZWSYPM-REWPJTCUSA-N 0.000 claims 1
- PQGWCQMKIOYQOC-GOTSBHOMSA-N [(3s)-4-(4-butoxycarbonylpiperazin-1-yl)-3-[[2-(3-fluorophenyl)-6-[(3s)-3-methoxypyrrolidin-1-yl]pyrimidine-4-carbonyl]amino]-4-oxobutyl]phosphonic acid Chemical compound C1CN(C(=O)OCCCC)CCN1C(=O)[C@H](CCP(O)(O)=O)NC(=O)C1=CC(N2C[C@H](CC2)OC)=NC(C=2C=C(F)C=CC=2)=N1 PQGWCQMKIOYQOC-GOTSBHOMSA-N 0.000 claims 1
- XBQBBYGZIYOSOA-GOTSBHOMSA-N [(3s)-4-(4-butoxycarbonylpiperazin-1-yl)-3-[[2-(4-fluorophenyl)-6-[(3s)-3-methoxypyrrolidin-1-yl]pyrimidine-4-carbonyl]amino]-4-oxobutyl]phosphonic acid Chemical compound C1CN(C(=O)OCCCC)CCN1C(=O)[C@H](CCP(O)(O)=O)NC(=O)C1=CC(N2C[C@H](CC2)OC)=NC(C=2C=CC(F)=CC=2)=N1 XBQBBYGZIYOSOA-GOTSBHOMSA-N 0.000 claims 1
- FWHNLSYJWYDCKC-QHCPKHFHSA-N [(3s)-4-(4-butoxycarbonylpiperazin-1-yl)-3-[[6-(4-methylpiperazin-1-yl)-2-phenylpyrimidine-4-carbonyl]amino]-4-oxobutyl]phosphonic acid Chemical compound C1CN(C(=O)OCCCC)CCN1C(=O)[C@H](CCP(O)(O)=O)NC(=O)C1=CC(N2CCN(C)CC2)=NC(C=2C=CC=CC=2)=N1 FWHNLSYJWYDCKC-QHCPKHFHSA-N 0.000 claims 1
- VXCDBNNDTXVRBR-QFIPXVFZSA-N [(3s)-4-(4-butoxycarbonylpiperazin-1-yl)-3-[[6-(4-methylpyrazol-1-yl)-2-phenylpyrimidine-4-carbonyl]amino]-4-oxobutyl]phosphonic acid Chemical compound C1CN(C(=O)OCCCC)CCN1C(=O)[C@H](CCP(O)(O)=O)NC(=O)C1=CC(N2N=CC(C)=C2)=NC(C=2C=CC=CC=2)=N1 VXCDBNNDTXVRBR-QFIPXVFZSA-N 0.000 claims 1
- AQTOYNHDZQFFPC-ZEQRLZLVSA-N [(3s)-4-(4-butoxycarbonylpiperazin-1-yl)-3-[[6-[(3s)-3-methoxypyrrolidin-1-yl]-2-(4-methylphenyl)pyrimidine-4-carbonyl]amino]-4-oxobutyl]phosphonic acid Chemical compound C1CN(C(=O)OCCCC)CCN1C(=O)[C@H](CCP(O)(O)=O)NC(=O)C1=CC(N2C[C@H](CC2)OC)=NC(C=2C=CC(C)=CC=2)=N1 AQTOYNHDZQFFPC-ZEQRLZLVSA-N 0.000 claims 1
- GIMIIIXPMMULNJ-GOTSBHOMSA-N [(3s)-4-(4-butoxycarbonylpiperazin-1-yl)-3-[[6-[(3s)-3-methoxypyrrolidin-1-yl]-2-[3-(trifluoromethyl)phenyl]pyrimidine-4-carbonyl]amino]-4-oxobutyl]phosphonic acid Chemical compound C1CN(C(=O)OCCCC)CCN1C(=O)[C@H](CCP(O)(O)=O)NC(=O)C1=CC(N2C[C@H](CC2)OC)=NC(C=2C=C(C=CC=2)C(F)(F)F)=N1 GIMIIIXPMMULNJ-GOTSBHOMSA-N 0.000 claims 1
- CFEYHNMCRFLPRJ-GOTSBHOMSA-N [(3s)-4-(4-butoxycarbonylpiperazin-1-yl)-3-[[6-[(3s)-3-methoxypyrrolidin-1-yl]-2-phenylpyrimidine-4-carbonyl]amino]-4-oxobutyl]phosphonic acid Chemical compound C1CN(C(=O)OCCCC)CCN1C(=O)[C@H](CCP(O)(O)=O)NC(=O)C1=CC(N2C[C@H](CC2)OC)=NC(C=2C=CC=CC=2)=N1 CFEYHNMCRFLPRJ-GOTSBHOMSA-N 0.000 claims 1
- IBGIVRQZWVXAEG-NRFANRHFSA-N [(3s)-4-(4-butoxycarbonylpiperazin-1-yl)-4-oxo-3-[(2-phenyl-6-pyrazol-1-ylpyrimidine-4-carbonyl)amino]butyl]phosphonic acid Chemical compound C1CN(C(=O)OCCCC)CCN1C(=O)[C@H](CCP(O)(O)=O)NC(=O)C1=CC(N2N=CC=C2)=NC(C=2C=CC=CC=2)=N1 IBGIVRQZWVXAEG-NRFANRHFSA-N 0.000 claims 1
- BUWUPMICNQDCHB-QFIPXVFZSA-N [(3s)-4-(4-butoxycarbonylpiperazin-1-yl)-4-oxo-3-[(2-phenyl-6-pyrrolidin-1-ylpyrimidine-4-carbonyl)amino]butyl]phosphonic acid Chemical compound C1CN(C(=O)OCCCC)CCN1C(=O)[C@H](CCP(O)(O)=O)NC(=O)C1=CC(N2CCCC2)=NC(C=2C=CC=CC=2)=N1 BUWUPMICNQDCHB-QFIPXVFZSA-N 0.000 claims 1
- ZAWOAAIHTIFLOB-NRFANRHFSA-N [(3s)-4-(4-butoxycarbonylpiperazin-1-yl)-4-oxo-3-[[2-phenyl-6-(propan-2-ylamino)pyrimidine-4-carbonyl]amino]butyl]phosphonic acid Chemical compound C1CN(C(=O)OCCCC)CCN1C(=O)[C@H](CCP(O)(O)=O)NC(=O)C1=CC(NC(C)C)=NC(C=2C=CC=CC=2)=N1 ZAWOAAIHTIFLOB-NRFANRHFSA-N 0.000 claims 1
- SGNBESSYWCSYHR-VXKWHMMOSA-N [(3s)-4-(4-butoxycarbonylpiperazin-1-yl)-4-oxo-3-[[6-[(3s)-oxolan-3-yl]oxy-2-phenylpyrimidine-4-carbonyl]amino]butyl]phosphonic acid Chemical compound C1CN(C(=O)OCCCC)CCN1C(=O)[C@H](CCP(O)(O)=O)NC(=O)C1=CC(O[C@@H]2COCC2)=NC(C=2C=CC=CC=2)=N1 SGNBESSYWCSYHR-VXKWHMMOSA-N 0.000 claims 1
- IVFUOMFADLXNHN-SFTDATJTSA-N [(3s)-4-(4-ethoxycarbonylpiperazin-1-yl)-3-[[6-[(3s)-3-methoxypyrrolidin-1-yl]-2-phenylpyrimidine-4-carbonyl]amino]-4-oxobutyl]phosphonic acid Chemical compound C1CN(C(=O)OCC)CCN1C(=O)[C@H](CCP(O)(O)=O)NC(=O)C1=CC(N2C[C@H](CC2)OC)=NC(C=2C=CC=CC=2)=N1 IVFUOMFADLXNHN-SFTDATJTSA-N 0.000 claims 1
- JUQBEMMMBAKFBJ-BJKOFHAPSA-N [(4r)-5-(4-butoxycarbonylpiperazin-1-yl)-4-[[6-[(3s)-3-methoxypyrrolidin-1-yl]-2-phenylpyrimidine-4-carbonyl]amino]-5-oxopentyl]phosphonic acid Chemical compound C1CN(C(=O)OCCCC)CCN1C(=O)[C@@H](CCCP(O)(O)=O)NC(=O)C1=CC(N2C[C@H](CC2)OC)=NC(C=2C=CC=CC=2)=N1 JUQBEMMMBAKFBJ-BJKOFHAPSA-N 0.000 claims 1
- JUQBEMMMBAKFBJ-ZEQRLZLVSA-N [(4s)-5-(4-butoxycarbonylpiperazin-1-yl)-4-[[6-[(3s)-3-methoxypyrrolidin-1-yl]-2-phenylpyrimidine-4-carbonyl]amino]-5-oxopentyl]phosphonic acid Chemical compound C1CN(C(=O)OCCCC)CCN1C(=O)[C@H](CCCP(O)(O)=O)NC(=O)C1=CC(N2C[C@H](CC2)OC)=NC(C=2C=CC=CC=2)=N1 JUQBEMMMBAKFBJ-ZEQRLZLVSA-N 0.000 claims 1
- YZYRDBKQJNQGSS-JINQPTGOSA-N [2-(4-butoxycarbonylpiperazin-1-yl)-1-[[6-[(3s)-3-methoxypyrrolidin-1-yl]-2-phenylpyrimidine-4-carbonyl]amino]-2-oxoethyl]phosphonic acid Chemical compound C1CN(C(=O)OCCCC)CCN1C(=O)C(P(O)(O)=O)NC(=O)C1=CC(N2C[C@H](CC2)OC)=NC(C=2C=CC=CC=2)=N1 YZYRDBKQJNQGSS-JINQPTGOSA-N 0.000 claims 1
- YTAUPEZWFNCNBZ-CTLOQAHHSA-N [2-[2-(4-butoxycarbonylpiperazin-1-yl)-1-[[6-[(3s)-3-methoxypyrrolidin-1-yl]-2-phenylpyrimidine-4-carbonyl]amino]-2-oxoethyl]phenyl]phosphonic acid Chemical compound C1CN(C(=O)OCCCC)CCN1C(=O)C(C=1C(=CC=CC=1)P(O)(O)=O)NC(=O)C1=CC(N2C[C@H](CC2)OC)=NC(C=2C=CC=CC=2)=N1 YTAUPEZWFNCNBZ-CTLOQAHHSA-N 0.000 claims 1
- GNCLYDRJKVFSPD-GMMLNUAGSA-N [3-[2-(4-butoxycarbonylpiperazin-1-yl)-1-[[6-[(3s)-3-methoxypyrrolidin-1-yl]-2-phenylpyrimidine-4-carbonyl]amino]-2-oxoethyl]phenyl]phosphonic acid Chemical compound C1CN(C(=O)OCCCC)CCN1C(=O)C(C=1C=C(C=CC=1)P(O)(O)=O)NC(=O)C1=CC(N2C[C@H](CC2)OC)=NC(C=2C=CC=CC=2)=N1 GNCLYDRJKVFSPD-GMMLNUAGSA-N 0.000 claims 1
- KUFSGJUDTJTJJX-DCCUJTHKSA-N [3-[2-(4-ethoxycarbonylpiperazin-1-yl)-1-[[6-[(3s)-3-methoxypyrrolidin-1-yl]-2-phenylpyrimidine-4-carbonyl]amino]-2-oxoethyl]phenyl]phosphonic acid Chemical compound C1CN(C(=O)OCC)CCN1C(=O)C(C=1C=C(C=CC=1)P(O)(O)=O)NC(=O)C1=CC(N2C[C@H](CC2)OC)=NC(C=2C=CC=CC=2)=N1 KUFSGJUDTJTJJX-DCCUJTHKSA-N 0.000 claims 1
- IPPVDPLZYBRZDT-JDXGNMNLSA-N [4-[(2s)-3-(4-butoxycarbonylpiperazin-1-yl)-2-[[6-[(3s)-3-methoxypyrrolidin-1-yl]-2-phenylpyrimidine-4-carbonyl]amino]-3-oxopropyl]phenyl]methylphosphonic acid Chemical compound C1CN(C(=O)OCCCC)CCN1C(=O)[C@@H](NC(=O)C=1N=C(N=C(C=1)N1C[C@H](CC1)OC)C=1C=CC=CC=1)CC1=CC=C(CP(O)(O)=O)C=C1 IPPVDPLZYBRZDT-JDXGNMNLSA-N 0.000 claims 1
- BYVKMTXSIMUWIF-WNJJXGMVSA-N [4-[(2s)-3-(4-butoxycarbonylpiperazin-1-yl)-2-[[6-[(3s)-3-methoxypyrrolidin-1-yl]-2-phenylpyrimidine-4-carbonyl]amino]-3-oxopropyl]phenyl]phosphonic acid Chemical compound C1CN(C(=O)OCCCC)CCN1C(=O)[C@@H](NC(=O)C=1N=C(N=C(C=1)N1C[C@H](CC1)OC)C=1C=CC=CC=1)CC1=CC=C(P(O)(O)=O)C=C1 BYVKMTXSIMUWIF-WNJJXGMVSA-N 0.000 claims 1
- HFOYTSRCWYVJQB-XCZPVHLTSA-N [4-[(2s)-3-(4-ethoxycarbonylpiperazin-1-yl)-2-[[6-[(3s)-3-methoxypyrrolidin-1-yl]-2-phenylpyrimidine-4-carbonyl]amino]-3-oxopropyl]phenyl]methylphosphonic acid Chemical compound C1CN(C(=O)OCC)CCN1C(=O)[C@@H](NC(=O)C=1N=C(N=C(C=1)N1C[C@H](CC1)OC)C=1C=CC=CC=1)CC1=CC=C(CP(O)(O)=O)C=C1 HFOYTSRCWYVJQB-XCZPVHLTSA-N 0.000 claims 1
- JXUBCDKYFUXBIZ-GMMLNUAGSA-N [4-[2-(4-butoxycarbonylpiperazin-1-yl)-1-[[6-[(3s)-3-methoxypyrrolidin-1-yl]-2-phenylpyrimidine-4-carbonyl]amino]-2-oxoethyl]phenyl]phosphonic acid Chemical compound C1CN(C(=O)OCCCC)CCN1C(=O)C(C=1C=CC(=CC=1)P(O)(O)=O)NC(=O)C1=CC(N2C[C@H](CC2)OC)=NC(C=2C=CC=CC=2)=N1 JXUBCDKYFUXBIZ-GMMLNUAGSA-N 0.000 claims 1
- MMRJFTURRVEHMQ-DCCUJTHKSA-N [4-[2-(4-ethoxycarbonylpiperazin-1-yl)-1-[[6-[(3s)-3-methoxypyrrolidin-1-yl]-2-phenylpyrimidine-4-carbonyl]amino]-2-oxoethyl]phenyl]phosphonic acid Chemical compound C1CN(C(=O)OCC)CCN1C(=O)C(C=1C=CC(=CC=1)P(O)(O)=O)NC(=O)C1=CC(N2C[C@H](CC2)OC)=NC(C=2C=CC=CC=2)=N1 MMRJFTURRVEHMQ-DCCUJTHKSA-N 0.000 claims 1
- MQAOVLHAVIBNAY-AHWVRZQESA-N acetyloxymethoxy-[(2r)-3-(4-butoxycarbonylpiperazin-1-yl)-2-[[6-[(3s)-3-methoxypyrrolidin-1-yl]-2-phenylpyrimidine-4-carbonyl]amino]-3-oxopropyl]phosphinic acid Chemical compound C1CN(C(=O)OCCCC)CCN1C(=O)[C@H](CP(O)(=O)OCOC(C)=O)NC(=O)C1=CC(N2C[C@H](CC2)OC)=NC(C=2C=CC=CC=2)=N1 MQAOVLHAVIBNAY-AHWVRZQESA-N 0.000 claims 1
- 125000004849 alkoxymethyl group Chemical group 0.000 claims 1
- 125000003710 aryl alkyl group Chemical group 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims 1
- FJXQBSRQDREGOV-YTMVLYRLSA-N bis(2-methylpropanoyloxy)methoxy-[(2R)-3-(4-butoxycarbonylpiperazin-1-yl)-2-[[6-[(3S)-3-methoxypyrrolidin-1-yl]-2-phenylpyrimidine-4-carbonyl]amino]-3-oxopropylidene]-oxidophosphanium Chemical compound C1CN(C(=O)OCCCC)CCN1C(=O)[C@H](C=P(=O)OC(OC(=O)C(C)C)OC(=O)C(C)C)NC(=O)C1=CC(N2C[C@H](CC2)OC)=NC(C=2C=CC=CC=2)=N1 FJXQBSRQDREGOV-YTMVLYRLSA-N 0.000 claims 1
- XNHPAUSTRILULF-VMPREFPWSA-N bis(2-methylpropanoyloxy)methoxy-[(3S)-4-(4-butoxycarbonylpiperazin-1-yl)-3-[[6-[(3S)-3-methoxypyrrolidin-1-yl]-2-phenylpyrimidine-4-carbonyl]amino]-4-oxobutylidene]-oxidophosphanium Chemical compound C1CN(C(=O)OCCCC)CCN1C(=O)[C@H](CC=P(=O)OC(OC(=O)C(C)C)OC(=O)C(C)C)NC(=O)C1=CC(N2C[C@H](CC2)OC)=NC(C=2C=CC=CC=2)=N1 XNHPAUSTRILULF-VMPREFPWSA-N 0.000 claims 1
- VLDAIAKPQKMMQE-AHWVRZQESA-N butyl 4-[(2r)-2-[[6-[(3s)-3-methoxypyrrolidin-1-yl]-2-phenylpyrimidine-4-carbonyl]amino]-3-(2-oxo-1,3,2$l^{5}-dioxaphosphinan-2-yl)propanoyl]piperazine-1-carboxylate Chemical compound C1CN(C(=O)OCCCC)CCN1C(=O)[C@@H](NC(=O)C=1N=C(N=C(C=1)N1C[C@H](CC1)OC)C=1C=CC=CC=1)CP1(=O)OCCCO1 VLDAIAKPQKMMQE-AHWVRZQESA-N 0.000 claims 1
- PEDRAIDJIQOSRC-VNWQBRMLSA-N butyl 4-[(2r)-2-[[6-[(3s)-3-methoxypyrrolidin-1-yl]-2-phenylpyrimidine-4-carbonyl]amino]-3-(2-oxo-4h-1,3,2$l^{5}-benzodioxaphosphinin-2-yl)propanoyl]piperazine-1-carboxylate Chemical compound C1CN(C(=O)OCCCC)CCN1C(=O)[C@@H](NC(=O)C=1N=C(N=C(C=1)N1C[C@H](CC1)OC)C=1C=CC=CC=1)CP1(=O)OC2=CC=CC=C2CO1 PEDRAIDJIQOSRC-VNWQBRMLSA-N 0.000 claims 1
- ZVPLMMQALPFVSK-MEMSPDJJSA-N butyl 4-[(2r)-2-[[6-[(3s)-3-methoxypyrrolidin-1-yl]-2-phenylpyrimidine-4-carbonyl]amino]-3-(2-oxo-8-propan-2-yl-4h-1,3,2$l^{5}-benzodioxaphosphinin-2-yl)propanoyl]piperazine-1-carboxylate Chemical compound C1CN(C(=O)OCCCC)CCN1C(=O)[C@@H](NC(=O)C=1N=C(N=C(C=1)N1C[C@H](CC1)OC)C=1C=CC=CC=1)CP1(=O)OC2=C(C(C)C)C=CC=C2CO1 ZVPLMMQALPFVSK-MEMSPDJJSA-N 0.000 claims 1
- KUANPMBUHXDBFU-XMRDPMTESA-N butyl 4-[(2r)-2-[[6-[(3s)-3-methoxypyrrolidin-1-yl]-2-phenylpyrimidine-4-carbonyl]amino]-3-(8-methyl-2-oxo-4h-1,3,2$l^{5}-benzodioxaphosphinin-2-yl)propanoyl]piperazine-1-carboxylate Chemical compound C1CN(C(=O)OCCCC)CCN1C(=O)[C@@H](NC(=O)C=1N=C(N=C(C=1)N1C[C@H](CC1)OC)C=1C=CC=CC=1)CP1(=O)OC2=C(C)C=CC=C2CO1 KUANPMBUHXDBFU-XMRDPMTESA-N 0.000 claims 1
- KQUVGYMFBWPPQO-NPRSNXAQSA-N butyl 4-[(2r)-3-[bis(1-cyclohexyloxycarbonyloxyethoxy)phosphoryl]-2-[[6-[(3s)-3-methoxypyrrolidin-1-yl]-2-phenylpyrimidine-4-carbonyl]amino]propanoyl]piperazine-1-carboxylate Chemical compound C1CN(C(=O)OCCCC)CCN1C(=O)[C@@H](NC(=O)C=1N=C(N=C(C=1)N1C[C@H](CC1)OC)C=1C=CC=CC=1)CP(=O)(OC(C)OC(=O)OC1CCCCC1)OC(C)OC(=O)OC1CCCCC1 KQUVGYMFBWPPQO-NPRSNXAQSA-N 0.000 claims 1
- MNOYKEOAZCXQAU-PUUNBFJPSA-N butyl 4-[(2r)-3-[bis(1-ethoxycarbonyloxyethoxy)phosphoryl]-2-[[6-[(3s)-3-methoxypyrrolidin-1-yl]-2-phenylpyrimidine-4-carbonyl]amino]propanoyl]piperazine-1-carboxylate Chemical compound C1CN(C(=O)OCCCC)CCN1C(=O)[C@H](CP(=O)(OC(C)OC(=O)OCC)OC(C)OC(=O)OCC)NC(=O)C1=CC(N2C[C@H](CC2)OC)=NC(C=2C=CC=CC=2)=N1 MNOYKEOAZCXQAU-PUUNBFJPSA-N 0.000 claims 1
- DZWWOUXSLVZXAX-REKAVORPSA-N butyl 4-[(2r)-3-[bis(1-propan-2-yloxycarbonyloxyethoxy)phosphoryl]-2-[[6-[(3s)-3-methoxypyrrolidin-1-yl]-2-phenylpyrimidine-4-carbonyl]amino]propanoyl]piperazine-1-carboxylate Chemical compound C1CN(C(=O)OCCCC)CCN1C(=O)[C@H](CP(=O)(OC(C)OC(=O)OC(C)C)OC(C)OC(=O)OC(C)C)NC(=O)C1=CC(N2C[C@H](CC2)OC)=NC(C=2C=CC=CC=2)=N1 DZWWOUXSLVZXAX-REKAVORPSA-N 0.000 claims 1
- DLDVKQHTXRWSQJ-UWPFYFSQSA-N butyl 4-[(2r)-3-[bis(1-propanoyloxyethoxy)phosphoryl]-2-[[6-[(3s)-3-methoxypyrrolidin-1-yl]-2-phenylpyrimidine-4-carbonyl]amino]propanoyl]piperazine-1-carboxylate Chemical compound C1CN(C(=O)OCCCC)CCN1C(=O)[C@H](CP(=O)(OC(C)OC(=O)CC)OC(C)OC(=O)CC)NC(=O)C1=CC(N2C[C@H](CC2)OC)=NC(C=2C=CC=CC=2)=N1 DLDVKQHTXRWSQJ-UWPFYFSQSA-N 0.000 claims 1
- SWSZGIAQXZBHBU-SMCANUKXSA-N butyl 4-[(2r)-3-[bis(2,2-dimethylpropanoyloxymethoxy)phosphoryl]-2-[[6-[(3s)-3-methoxypyrrolidin-1-yl]-2-phenylpyrimidine-4-carbonyl]amino]propanoyl]piperazine-1-carboxylate Chemical compound C1CN(C(=O)OCCCC)CCN1C(=O)[C@H](CP(=O)(OCOC(=O)C(C)(C)C)OCOC(=O)C(C)(C)C)NC(=O)C1=CC(N2C[C@H](CC2)OC)=NC(C=2C=CC=CC=2)=N1 SWSZGIAQXZBHBU-SMCANUKXSA-N 0.000 claims 1
- ODMDAAXOPRGRLA-YTMVLYRLSA-N butyl 4-[(2r)-3-[bis(acetyloxymethoxy)phosphoryl]-2-[[6-[(3s)-3-methoxypyrrolidin-1-yl]-2-phenylpyrimidine-4-carbonyl]amino]propanoyl]piperazine-1-carboxylate Chemical compound C1CN(C(=O)OCCCC)CCN1C(=O)[C@H](CP(=O)(OCOC(C)=O)OCOC(C)=O)NC(=O)C1=CC(N2C[C@H](CC2)OC)=NC(C=2C=CC=CC=2)=N1 ODMDAAXOPRGRLA-YTMVLYRLSA-N 0.000 claims 1
- AIOOGEYTPXEZQM-UBCZYAQWSA-N butyl 4-[(2r)-3-[bis[(3-oxo-1h-2-benzofuran-1-yl)oxy]phosphoryl]-2-[[6-[(3s)-3-methoxypyrrolidin-1-yl]-2-phenylpyrimidine-4-carbonyl]amino]propanoyl]piperazine-1-carboxylate Chemical compound C1CN(C(=O)OCCCC)CCN1C(=O)[C@@H](NC(=O)C=1N=C(N=C(C=1)N1C[C@H](CC1)OC)C=1C=CC=CC=1)CP(=O)(OC1C2=CC=CC=C2C(=O)O1)OC1C2=CC=CC=C2C(=O)O1 AIOOGEYTPXEZQM-UBCZYAQWSA-N 0.000 claims 1
- YQZSOZKXAIKVLF-YTMVLYRLSA-N butyl 4-[(2r)-3-[bis[(5-methyl-2-oxo-1,3-dioxol-4-yl)methoxy]phosphoryl]-2-[[6-[(3s)-3-methoxypyrrolidin-1-yl]-2-phenylpyrimidine-4-carbonyl]amino]propanoyl]piperazine-1-carboxylate Chemical compound C1CN(C(=O)OCCCC)CCN1C(=O)[C@@H](NC(=O)C=1N=C(N=C(C=1)N1C[C@H](CC1)OC)C=1C=CC=CC=1)CP(=O)(OCC1=C(OC(=O)O1)C)OCC1=C(C)OC(=O)O1 YQZSOZKXAIKVLF-YTMVLYRLSA-N 0.000 claims 1
- KDUMFOYUHGOVME-REKAVORPSA-N butyl 4-[(2r)-3-[bis[1-(2,2-dimethylpropanoyloxy)ethoxy]phosphoryl]-2-[[6-[(3s)-3-methoxypyrrolidin-1-yl]-2-phenylpyrimidine-4-carbonyl]amino]propanoyl]piperazine-1-carboxylate Chemical compound C1CN(C(=O)OCCCC)CCN1C(=O)[C@H](CP(=O)(OC(C)OC(=O)C(C)(C)C)OC(C)OC(=O)C(C)(C)C)NC(=O)C1=CC(N2C[C@H](CC2)OC)=NC(C=2C=CC=CC=2)=N1 KDUMFOYUHGOVME-REKAVORPSA-N 0.000 claims 1
- YPJKPZFQNWOGEQ-IEUSEWSZSA-N butyl 4-[(2r)-3-[bis[1-(2-methylpropanoyloxy)ethoxy]phosphoryl]-2-[[6-[(3s)-3-methoxypyrrolidin-1-yl]-2-phenylpyrimidine-4-carbonyl]amino]propanoyl]piperazine-1-carboxylate Chemical compound C1CN(C(=O)OCCCC)CCN1C(=O)[C@H](CP(=O)(OC(C)OC(=O)C(C)C)OC(C)OC(=O)C(C)C)NC(=O)C1=CC(N2C[C@H](CC2)OC)=NC(C=2C=CC=CC=2)=N1 YPJKPZFQNWOGEQ-IEUSEWSZSA-N 0.000 claims 1
- JYYKYKRSHVVVQT-JSXFGMRASA-N butyl 4-[(2r)-3-bis(phenylmethoxy)phosphoryl-2-[[6-[(3s)-3-methoxypyrrolidin-1-yl]-2-phenylpyrimidine-4-carbonyl]amino]propanoyl]piperazine-1-carboxylate Chemical compound C1CN(C(=O)OCCCC)CCN1C(=O)[C@@H](NC(=O)C=1N=C(N=C(C=1)N1C[C@H](CC1)OC)C=1C=CC=CC=1)CP(=O)(OCC=1C=CC=CC=1)OCC1=CC=CC=C1 JYYKYKRSHVVVQT-JSXFGMRASA-N 0.000 claims 1
- ZALLVONZQZIMCH-ILUGTUFDSA-N butyl 4-[(2r)-3-bis[[(2s)-1-ethoxy-1-oxopropan-2-yl]oxy]phosphoryl-2-[[6-[(3s)-3-methoxypyrrolidin-1-yl]-2-phenylpyrimidine-4-carbonyl]amino]propanoyl]piperazine-1-carboxylate Chemical compound C1CN(C(=O)OCCCC)CCN1C(=O)[C@H](CP(=O)(O[C@@H](C)C(=O)OCC)O[C@@H](C)C(=O)OCC)NC(=O)C1=CC(N2C[C@H](CC2)OC)=NC(C=2C=CC=CC=2)=N1 ZALLVONZQZIMCH-ILUGTUFDSA-N 0.000 claims 1
- QSOZEHIASCYOEA-LRHLLKFHSA-N butyl 4-[(2r)-3-diphenoxyphosphoryl-2-[[6-[(3s)-3-methoxypyrrolidin-1-yl]-2-phenylpyrimidine-4-carbonyl]amino]propanoyl]piperazine-1-carboxylate Chemical compound C1CN(C(=O)OCCCC)CCN1C(=O)[C@@H](NC(=O)C=1N=C(N=C(C=1)N1C[C@H](CC1)OC)C=1C=CC=CC=1)CP(=O)(OC=1C=CC=CC=1)OC1=CC=CC=C1 QSOZEHIASCYOEA-LRHLLKFHSA-N 0.000 claims 1
- ACWKYDXOGLAEJT-CONSDPRKSA-N butyl 4-[(2s)-4-[bis(2,2-dimethylpropanoyloxymethoxy)phosphoryl]-2-[[6-[(3s)-3-methoxypyrrolidin-1-yl]-2-phenylpyrimidine-4-carbonyl]amino]butanoyl]piperazine-1-carboxylate Chemical compound C1CN(C(=O)OCCCC)CCN1C(=O)[C@H](CCP(=O)(OCOC(=O)C(C)(C)C)OCOC(=O)C(C)(C)C)NC(=O)C1=CC(N2C[C@H](CC2)OC)=NC(C=2C=CC=CC=2)=N1 ACWKYDXOGLAEJT-CONSDPRKSA-N 0.000 claims 1
- ZRJPWZPYLGZSTP-LQJZCPKCSA-N butyl 4-[(2s)-4-[bis[2-(2,2-dimethylpropanoyloxy)ethoxy]phosphoryl]-2-[[6-[(3s)-3-methoxypyrrolidin-1-yl]-2-phenylpyrimidine-4-carbonyl]amino]butanoyl]piperazine-1-carboxylate Chemical compound C1CN(C(=O)OCCCC)CCN1C(=O)[C@H](CCP(=O)(OCCOC(=O)C(C)(C)C)OCCOC(=O)C(C)(C)C)NC(=O)C1=CC(N2C[C@H](CC2)OC)=NC(C=2C=CC=CC=2)=N1 ZRJPWZPYLGZSTP-LQJZCPKCSA-N 0.000 claims 1
- PCUISYIUKKPEIH-BDYUSTAISA-N di(butanoyloxy)methoxy-[(2R)-3-(4-ethoxycarbonylpiperazin-1-yl)-2-[[6-[(3S)-3-methoxypyrrolidin-1-yl]-2-phenylpyrimidine-4-carbonyl]amino]-3-oxopropylidene]-oxidophosphanium Chemical compound N([C@@H](C=P(=O)OC(OC(=O)CCC)OC(=O)CCC)C(=O)N1CCN(CC1)C(=O)OCC)C(=O)C(N=1)=CC(N2C[C@H](CC2)OC)=NC=1C1=CC=CC=C1 PCUISYIUKKPEIH-BDYUSTAISA-N 0.000 claims 1
- PCUISYIUKKPEIH-AHKZPQOWSA-N di(butanoyloxy)methoxy-[(2S)-3-(4-ethoxycarbonylpiperazin-1-yl)-2-[[6-[(3S)-3-methoxypyrrolidin-1-yl]-2-phenylpyrimidine-4-carbonyl]amino]-3-oxopropylidene]-oxidophosphanium Chemical compound N([C@H](C=P(=O)OC(OC(=O)CCC)OC(=O)CCC)C(=O)N1CCN(CC1)C(=O)OCC)C(=O)C(N=1)=CC(N2C[C@H](CC2)OC)=NC=1C1=CC=CC=C1 PCUISYIUKKPEIH-AHKZPQOWSA-N 0.000 claims 1
- BXZMXXJYQWIEJI-DITALETJSA-N di(butanoyloxy)methoxy-[4-[(2S)-3-(4-ethoxycarbonylpiperazin-1-yl)-2-[[6-[(3S)-3-methoxypyrrolidin-1-yl]-2-phenylpyrimidine-4-carbonyl]amino]-3-oxopropyl]cyclohexa-2,4-dien-1-ylidene]-oxidophosphanium Chemical compound C1=CC(=P(=O)OC(OC(=O)CCC)OC(=O)CCC)CC=C1C[C@@H](C(=O)N1CCN(CC1)C(=O)OCC)NC(=O)C1=CC(N2C[C@H](CC2)OC)=NC(C=2C=CC=CC=2)=N1 BXZMXXJYQWIEJI-DITALETJSA-N 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- BIICBLXOQXGKFB-BDYUSTAISA-N ethyl 4-[(2r)-3-[bis(acetyloxymethoxy)phosphoryl]-2-[[6-[(3s)-3-methoxypyrrolidin-1-yl]-2-phenylpyrimidine-4-carbonyl]amino]propanoyl]piperazine-1-carboxylate Chemical compound C1CN(C(=O)OCC)CCN1C(=O)[C@H](CP(=O)(OCOC(C)=O)OCOC(C)=O)NC(=O)C1=CC(N2C[C@H](CC2)OC)=NC(C=2C=CC=CC=2)=N1 BIICBLXOQXGKFB-BDYUSTAISA-N 0.000 claims 1
- BIICBLXOQXGKFB-AHKZPQOWSA-N ethyl 4-[(2s)-3-[bis(acetyloxymethoxy)phosphoryl]-2-[[6-[(3s)-3-methoxypyrrolidin-1-yl]-2-phenylpyrimidine-4-carbonyl]amino]propanoyl]piperazine-1-carboxylate Chemical compound C1CN(C(=O)OCC)CCN1C(=O)[C@@H](CP(=O)(OCOC(C)=O)OCOC(C)=O)NC(=O)C1=CC(N2C[C@H](CC2)OC)=NC(C=2C=CC=CC=2)=N1 BIICBLXOQXGKFB-AHKZPQOWSA-N 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 125000001072 heteroaryl group Chemical group 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000003884 phenylalkyl group Chemical group 0.000 claims 1
- 125000003226 pyrazolyl group Chemical group 0.000 claims 1
- FYXHWMQPCJOJCH-GMAHTHKFSA-N selatogrel Chemical compound C1CN(C(=O)OCCCC)CCN1C(=O)[C@H](CP(O)(O)=O)NC(=O)C1=CC(N2C[C@H](CC2)OC)=NC(C=2C=CC=CC=2)=N1 FYXHWMQPCJOJCH-GMAHTHKFSA-N 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
- C07F9/6571—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms
- C07F9/657163—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms the ring phosphorus atom being bound to at least one carbon atom
- C07F9/657181—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms the ring phosphorus atom being bound to at least one carbon atom the ring phosphorus atom and, at least, one ring oxygen atom being part of a (thio)phosphonic acid derivative
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
- C07F9/6581—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms
- C07F9/6584—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms having one phosphorus atom as ring hetero atom
- C07F9/65842—Cyclic amide derivatives of acids of phosphorus, in which one nitrogen atom belongs to the ring
- C07F9/65846—Cyclic amide derivatives of acids of phosphorus, in which one nitrogen atom belongs to the ring the phosphorus atom being part of a six-membered ring which may be condensed with another ring system
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Claims (16)
1. Spoj, naznačen time, da ima formulu I
[image]
gdje
R1 predstavlja fenil, gdje je fenil nesupstituiran ili supstituiran 1 do 3 puta (poželjno nesupstituiran ili supstituiran jednom ili dva puta, još poželjnije nesupstituiran ili supstituiran jednom te najbolje nesupstituiran) pomoću supstituenata svakog neovisno odabranog iz skupine koju čine halogen, metil, metoksi, trifluorometil i trifluorometoksi;
W predstavlja vezu, i R2 predstavlja alkil, hidroksialkil, alkoksialkil, cikloalkil, aril ili heteroaril; ili W predstavlja -O- i R2 predstavlja alkil, cikloalkil, hidroksialkil ili heterociklil; ili
W predstavlja -NR3-, R2 predstavlja alkil, alkoksikarbonilalkil, karboksialkil, hidroksialkil, alkoksialkil, heterociklil, cikloalkil, aril ili aralkil i R3 predstavlja vodik ili alkil; ili W predstavlja -NR3- te R2 i R3 tvore, zajedno s dušikom koji ih nosi, heterociklički prsten od 4 do 7 članova, gdje su članovi potrebni za kompletiranje spomenutog heterocikličkog prstena svaki neovisno odabrani od -CH2-, -CHRx-, -O-, -S-, -CO- i -NRy-, pri čemu se podrazumijeva da spomenuti heterociklički prsten ne sadrži više od jednog člana odabranog iz skupine koju čine -CHRx-, -O-, -S-, -CO- i
-NRy-, Rx predstavljajući hidroksi, hidroksimetil, alkoksimetil ili alkoksi i Ry predstavljajući vodik ili alkil; ili W predstavlja -NR3- te R2 i R3 tvore, zajedno s dušikom koji ih nosi, animidazolil-, pirazolil-, 1,2,3-triazolil- ili 1,2,4-triazolil-prsten, gdje taj prsten može biti supstituiran s alkilnom skupinom (posebno s metilnom skupinom);
Ra predstavlja vodik ili metil;
Rb predstavlja vodik ili metil;
R4 predstavlja alkoksi;
n predstavlja 0, 1, 2 ili 3, V predstavlja vezu, i m predstavlja 0; ili
n predstavlja 0 ili 1, V predstavlja fenil, i m predstavlja 0; ili
n predstavlja 1, V predstavlja fenil, i m predstavlja 1;
R5 i R8 su identični i svaki predstavlja hidroksi, nesupstituiran feniloksi, nesupstituiran benziloksi, skupinu -O-(CHR6)-O-C(=O)-R7, skupinu -O-(CHR6)-O-C(=O)-O-R7, skupinu -O-(CHR6)-C(=O)-O-R9, skupinu NH-(CHR10)-C(=O)-O-R9 ili skupinu -NH-C(CH3)2-C(=O)-O-R9; ili
R5 predstavlja hidroksi ili nesupstituiran feniloksi, i R8 predstavlja skupinu -O-(CH2)-O-C(=O)-R9 ili skupinu NH-CH(CH3)-C(=O)-O-R9; ili
P(O)R5R8 predstavlja skupinu odabranu od sljedećih struktura
[image]
[image]
gdje strelica označava točku priključenja na preostali dio spojeva formule I;
q predstavlja 1 ili 2;
R6 predstavlja vodik ili (C1-C3)alkil;
R7 predstavlja (C1-C4)alkil ili nesupstituiran (C3-C6)cikloalkil;
R9 predstavlja (C1-C4)alkil;
R10 predstavlja vodik, (C1-C4)alkil, nesupstituiran fenil ili nesupstituiran benzil;
R11 predstavlja vodik, (C1-C4)alkil ili (C1-C4)alkoksi;
ili farmaceutski prihvatljiva sol takvog spoja.
2. Spoj formule I prema zahtjevu 1, naznačen time, da V predstavlja vezu;
ili farmaceutski prihvatljiva sol takvog spoja.
3. Spoj formule I prema zahtjevu 1, naznačen time, da V predstavlja fenil;
ili farmaceutski prihvatljiva sol takvog spoja.
4. Spoj formule I prema zahtjevu 1, naznačen time, da kada V predstavlja vezu, tada m predstavlja 0 i n predstavlja 1, 2 ili 3;
ili farmaceutski prihvatljiva sol takvog spoja.
5. Spoj formule I prema bilo kojem zahtjevu od 1 do 4, naznačen time, da R1 predstavlja nesupstituiran fenil;
ili farmaceutski prihvatljiva sol takvog spoja.
6. Spoj formule I prema bilo kojem zahtjevu od 1 do 5, naznačen time, da W predstavlja vezu;
ili farmaceutski prihvatljiva sol takvog spoja.
7. Spoj formule I prema bilo kojem zahtjevu od 1 do 5, naznačen time, da W predstavlja -O-;
ili farmaceutski prihvatljiva sol takvog spoja.
8. Spoj formule I prema bilo kojem zahtjevu od 1 do 5, naznačen time, da W predstavlja -NR3-, R2 predstavlja alkil, alkoksikarbonilalkil, karboksialkil, hidroksialkil, alkoksialkil, heterociklil, cikloalkil, fenil ili fenilalkil i R3 predstavlja vodik ili alkil; ili da W predstavlja -NR3- te R2 i R3 tvore, zajedno s dušikom koji ih nosi, heterociklički prsten od 4 do 7 članova, gdje su članovi, potrebni za kompletiranje spomenutog heterocikličkog prstena, svaki neovisno odabrani od -CH2-, -CHRx-, -O- i -NRy-, pri čemu se podrazumijeva da spomenuti heterociklički prsten ne sadrži više od jednog člana odabranog iz skupine koju čine -CHRx-, -O- i -NRy-, Rx predstavljajući hidroksi, hidroksimetil, alkoksimetil ili alkoksi i Ry predstavljajući alkil ili da W predstavlja -NR3- te R2 i R3 tvore, zajedno s dušikom koji ih nosi, pirazolil-prsten koji može biti nesupstituiran ili monosupstituiran s alkilnom skupinom;
ili farmaceutski prihvatljiva sol takvog spoja.
9. Spoj formule I prema bilo kojem zahtjevu od 1 do 8, naznačen time, da R4 predstavlja (C2-C4)alkoksi;
ili farmaceutski prihvatljiva sol takvog spoja.
10. Spoj formule I prema bilo kojem zahtjevu od 1 do 9, naznačen time, da su R5 i R8 identični i predstavljaju hidroksi;
ili farmaceutski prihvatljiva sol takvog spoja.
11. Spoj formule I prema zahtjevu 1, naznačen time, da je odabran iz skupine koju čine:
4-((R)-2-{[6-((S)-3-metoksi-pirolidin-1-il)-2-fenil-pirimidin-4-karbonil]-amino}-3-fosfono-propionil)-piperazin-1-karboksilna kiselina etil ester;
4-((R)-2-{[6-((S)-3-metoksi-pirolidin-1-il)-2-fenil-pirimidin-4-karbonil]-amino}-3-fosfono-propionil)-piperazin-1-karboksilna kiselina butil ester;
4-((S)-2-{[6-((S)-3-metoksi-pirolidin-1-il)-2-fenil-pirimidin-4-karbonil]-amino}-3-fosfono-propionil)-piperazin-1-karboksilna kiselina etil ester;
4-((S)-2-{[6-((S)-3-metoksi-pirolidin-1-il)-2-fenil-pirimidin-4-karbonil]-amino}-4-fosfono-butiril)-piperazin-1-karboksilna kiselina etil ester;
4-((S)-2-{[6-((S)-3-metoksi-pirolidin-1-il)-2-fenil-pirimidin-4-karbonil]-amino}-4-fosfono-butiril)-piperazin-1-karboksilna kiselina butil ester;
4-((S)-2-{[6-((S)-3-metoksi-pirolidin-1-il)-2-fenil-pirimidin-4-karbonil]-amino}-3-fosfono-propionil)-piperazin-1-karboksilna kiselina butil ester;
4-{(S)-2-[(2-fenil-6-pirazol-1-il-pirimidin-4-karbonil)-amino]-4-fosfono-butiril}-piperazin-1-karboksilna kiselina butil ester;
4-((S)-2-{[6-(4-metil-pirazol-1-il)-2-fenil-pirimidin-4-karbonil]-amino}-4-fosfono-butiril)-piperazin-1-karboksilna kiselina butil ester;
4-[(S)-2-({2-fenil-6-[(S)-(tetrahidro-furan-3-il)oksi]-pirimidin-4-karbonil}-amino)-4-fosfono-butiril]-piperazin-1-karboksilna kiselina butil ester;
4-{(S)-2-[(2-fenil-6-pirolidin-1-il-pirimidin-4-karbonil)-amino]-4-fosfono-butiril}-piperazin-1-karboksilna kiselina butil ester;
4-{(S)-2-[(6-izopropilamino-2-fenil-pirimidin-4-karbonil)-amino]-4-fosfono-butiril}-piperazin-1-karboksilna kiselina butil ester;
4-{(S)-2-[(6-morfolin-4-il-2-fenil-pirimidin-4-karbonil)-amino]-4-fosfono-butiril}-piperazin-1-karboksilna kiselina butil ester;
4-((S)-2-{[6-(4-metil-piperazin-1-il)-2-fenil-pirimidin-4-karbonil]-amino}-4-fosfono-butiril)-piperazin-1-karboksilna kiselina butil ester;
4-{(R)-2-[(6-metilamino-2-fenil-pirimidin-4-karbonil)-amino]-3-fosfono-propionil}-piperazin-1-karboksilna kiselina butil ester;
4-{(R)-2-[(6-dimetilamino-2-fenil-pirimidin-4-karbonil)-amino]-3-fosfono-propionil}-piperazin-1-karboksilna kiselina butil ester;
4-{(R)-2-[(6-etilamino-2-fenil-pirimidin-4-karbonil)-amino]-3-fosfono-propionil}-piperazin-1-karboksilna kiselina butil ester;
4-{(R)-2-[(6-izopropilamino-2-fenil-pirimidin-4-karbonil)-amino]-3-fosfono-propionil}-piperazin-1-karboksilna kiselina butil ester;
4-((S)-2-{[2-(4-fluoro-fenil)-6-((S)-3-metoksi-pirolidin-1-il)-pirimidin-4-karbonil]-amino}-4-fosfono-butiril)-piperazin-1-karboksilna kiselina butil ester;
4-((S)-2-{[6-((S)-3-metoksi-pirolidin-1-il)-2-p-tolil-pirimidin-4-karbonil]-amino}-4-fosfono-butiril)-piperazin-1-karboksilna kiselina butil ester;
4-((S)-2-{[2-(2-fluoro-fenil)-6-((S)-3-metoksi-pirolidin-1-il)-pirimidin-4-karbonil]-amino}-4-fosfono-butiril)-piperazin-1-karboksilna kiselina butil ester;
4-((S)-2-{[2-(3-fluoro-fenil)-6-((S)-3-metoksi-pirolidin-1-il)-pirimidin-4-karbonil]-amino}-4-fosfono-butiril)-piperazin-1-karboksilna kiselina butil ester;
4-{(R)-2-[(6-metoksi-2-fenil-pirimidin-4-karbonil)-amino]-3-fosfono-propionil}-piperazin-1-karboksilna kiselina butil ester;
4-{(R)-2-[(6-metil-2-fenil-pirimidin-4-karbonil)-amino]-3-fosfono-propionil}-piperazin-1-karboksilna kiselina butil ester;
4-{(R)-2-[(6-ciklopropilamino-2-fenil-pirimidin-4-karbonil)-amino]-3-fosfono-propionil}-piperazin-1-karboksilna kiselina butil ester;
4-{(R)-2-[(2-fenil-6-fenilamino-pirimidin-4-karbonil)-amino]-3-fosfono-propionil}-piperazin-1-karboksilna kiselina butil ester;
4-{(R)-2-[(6-benzilamino-2-fenil-pirimidin-4-karbonil)-amino]-3-fosfono-propionil}-piperazin-1-karboksilna kiselina butil ester;
4-[(R)-2-((2-fenil-6-[(R)-(tetrahidro-furan-3-il)amino]-pirimidin-4-karbonil}-amino)-3-fosfono-propionil]-piperazin-1-karboksilna kiselina butil ester;
4-((R)-2-{[6-(3-hidroksi-pirolidin-1-il)-2-fenil-pirimidin-4-karbonil]-amino}-3-fosfono-propionil)-piperazin-1-karboksilna kiselina butil ester;
4-[(R)-2-({6-[(2-metoksi-etil)-metil-amino]-2-fenil-pirimidin-4-karbonil}-amino)-3-fosfono-propionil]-piperazin-1-karboksilna kiselina butil ester;
4-((R)-2-{[6-(2-etoksikarbonil-etilamino)-2-fenil-pirimidin-4-karbonil]-amino}-3-fosfono-propionil)-piperazin-1-karboksilna kiselina butil ester;
4-((R)-2-{[6-(2-karboksi-etilamino)-2-fenil-pirimidin-4-karbonil]-amino}-3-fosfono-propionil)-piperazin-1-karboksilna kiselina butil ester;
4-{(R)-2-[(2,6-difenil-pirimidin-4-karbonil)-amino]-3-fosfono-propionil}-piperazin-1-karboksilna kiselina butil ester;
4-{(R)-2-[(2-fenil-6-tiofen-3-il-pirimidin-4-karbonil)-amino]-3-fosfono-propionil}-piperazin-1-karboksilna kiselina butil ester;
4-((R)-2-{[6-(4-metoksi-fenil)-2-fenil-pirimidin-4-karbonil]-amino}-3-fosfono-propionil)-piperazin-1-karboksilna kiselina butil ester;
4-{(R)-2-[(6-ciklopropil-2-fenil-pirimidin-4-karbonil)-amino]-3-fosfono-propionil}-piperazin-1-karboksilna kiselina butil ester;
4-{(R)-2-[(6-butil-2-fenil-pirimidin-4-karbonil)-amino]-3-fosfono-propionil}-piperazin-1-karboksilna kiselina butil ester;
4-[(R)-2-({2-fenil-6-[(S)-(tetrahidro-furan-3-il)oksi]-pirimidin-4-karbonil}-amino)-3-fosfono-propionil]-piperazin-1-karboksilna kiselina butil ester;
4-((R)-2-{[6-((S)-3-metoksi-pirolidin-1-il)-2-fenil-pirimidin-4-karbonil]-amino}-3-fosfono-propionil)-2-metil-piperazin-1-karboksilna kiselina etil ester;
4-((R)-2-{[6-((S)-3-metoksi-pirolidin-1-il)-2-fenil-pirimidin-4-karbonil]-amino}-4-fosfono-butiril)-piperazin-1-karboksilna kiselina etil ester;
4-((R)-2-{[6-((S)-3-metoksi-pirolidin-1-il)-2-fenil-pirimidin-4-karbonil]-amino}-4-fosfono-butiril)-piperazin-1-karboksilna kiselina butil ester;
4-((R)-2-{[6-((1S,2S)-2-metoksimetil-ciklopropil)-2-fenil-pirimidin-4-karbonil]-amino}-3-fosfono-propionil)-piperazin-1-karboksilna kiselina butil ester;
4-((R)-2-{[6-((1S,2S)-2-hidroksimetil-ciklopropil)-2-fenil-pirimidin-4-karbonil]-amino}-3-fosfono-propionil)-piperazin-1-karboksilna kiselina butil ester;
4-((R)-2-{[6-(2-hidroksi-etilamino)-2-fenil-pirimidin-4-karbonil]-amino}-3-fosfono-propionil)-piperazin-1-karboksilna kiselina butil ester;
4-((R)-2-{[6-(2-hidroksimetil-piperidin-1-il)-2-fenil-pirimidin-4-karbonil]-amino}-3-fosfono-propionil)-piperazin-1-karboksilna kiselina butil ester;
4-((R)-2-{[6-(3-metoksi-propil)-2-fenil-pirimidin-4-karbonil]-amino}-3-fosfono-propionil)-piperazin-1-karboksilna kiselina butil ester;
4-((R)-2-{[6-(3-hidroksi-butil)-2-fenil-pirimidin-4-karbonil]-amino}-3-fosfono-propionil)-piperazin-1-karboksilna kiselina butil ester;
4-((S)-2- {[6-((S)-3-metoksi-pirolidin-1-il)-2-(3-trifluorometil-fenil)-pirimidin-4-karbonil]-amino}-4-fosfono-butiril)-piperazin-1-karboksilna kiselina butil ester;
4-((S)-4-[bis-(2,2-dimetil-propioniloksimetoksi)-fosforil]-2-{[6-((S)-3-metoksi-pirolidin-1-il)-2-fenil-pirimidin-4-karbonil]-amino}-butiril)-piperazin-1-karboksilna kiselina butil ester;
4-((S)-4-(bis-izobutiriloksimetoksi-fosforil)-2-{[6-((S)-3-metoksi-pirolidin-1-il)-2-fenil-pirimidin-4-karbonil]-amino}-butiril)-piperazin-1-karboksilna kiselina butil ester;
4-((S)-4-{bis-[(2,2-dimetil-propioniloksi)-etoksi]-fosforil}-2-{[6-((S)-3-metoksi-pirolidin-1-il)-2-fenil-pirimidin-4-karbonil]-amino}-butiril)-piperazin-1-karboksilna kiselina butil ester;
4-((R)-3-[bis-(2,2-dimetil-propioniloksimetoksi)-fosforil]-2-{[6-((S)-3-metoksi-pirolidin-1-il)-2-fenil-pirimidin-4-karbonil]-amino}-propionil)-piperazin-1-karboksilna kiselina butil ester;
4-((R)-3-{bis-[1-(2,2-dimetil-propioniloksi)-etoksi]-fosforil}-2-{[6-((S)-3-metoksi-pirolidin-1-il)-2-fenil-pirimidin-4-karbonil]-amino}-propionil)-piperazin-1-karboksilna kiselina butil ester;
4-((R)-3-[bis-(1-izobutiriloksi-etoksi)-fosforil]-2-{[6-((S)-3-metoksi-pirolidin-1-il)-2-fenil-pirimidin-4-karbonil]-amino}-propionil)-piperazin-1-karboksilna kiselina butil ester;
4-((R)-3-[bis-(1-propioniloksi-etoksi)-fosforil]-2-{[6-((S)-3-metoksi-pirolidin-1-il)-2-fenil-pirimidin-4-karbonil]-amino}-propionil)-piperazin-1-karboksilna kiselina butil ester;
4-((R)-3-(bis-izobutiriloksimetoksi-fosforil)-2-{[6-((S)-3-metoksi-pirolidin-1-il)-2-fenil-pirimidin-4-karbonil]-amino}-propionil)-piperazin-1-karboksilna kiselina butil ester;
4-(2-{[6-((S)-3-metoksi-pirolidin-1-il)-2-fenil-pirimidin-4-karbonil]-amino}-2-fosfono-acetil)-piperazin-1-karboksilna kiselina butil ester;
ili farmaceutski prihvatljiva sol takvog spoja.
12. Spoj formule I prema zahtjevu 1, naznačen time, da je odabran iz skupine koju čine:
4-((R)-2-{[6-(2-hidroksi-etoksi)-2-fenil-pirimidin-4-karbonil]-amino}-3-fosfono-propionil)-piperazin-1-karboksilna kiselina butil ester;
4-((S)-2-{[6-((S)-3-metoksi-pirolidin-1-il)-2-fenil-pirimidin-4-karbonil]-amino}-5-fosfono-pentanoil)-piperazin-1-karboksilna kiselina butil ester;
4-[(S)-2-{[6-((S)-3-metoksi-pirolidin-1-il)-2-fenil-pirimidin-4-karbonil]-amino}-3-(4-fosfono-fenil)-propionil]-piperazin-1-karboksilna kiselina etil ester;
4-[(S)-2-{[6-((S)-3-metoksi-pirolidin-1-il)-2-fenil-pirimidin-4-karbonil]-amino}-3-(4-fosfono-fenil)-propionil]-piperazin-1-karboksilna kiselina butil ester;
4-[(S)-2-{[6-((S)-3-metoksi-pirolidin-1-il)-2-fenil-pirimidin-4-karbonil]-amino}-3-(4-fosfonometil-fenil)-propionil]-piperazin-1-karboksilna kiselina etil ester;
4-[(S)-2-{[6-((S)-3-metoksi-pirolidin-1-il)-2-fenil-pirimidin-4-karbonil]-amino}-3-(4-fosfonometil-fenil)-propionil]-piperazin-1-karboksilna kiselina butil ester;
4-((R)-2-{[6-((S)-3-metoksi-pirolidin-1-il)-2-fenil-pirimidin-4-karbonil]-amino}-5-fosfono-pentanoil)-piperazin-1-karboksilna kiselina butil ester;
4-{(R)-2-[(6-izopropil-2-fenil-pirimidin-4-karbonil)-amino]-3-fosfono-propionil}-piperazin-1-karboksilna kiselina butil ester;
4-((R)-2-{[6-(3-metoksimetil-azetidin-1-il)-2-fenil-pirimidin-4-karbonil]-amino}-3-fosfono-propionil)-piperazin-1-karboksilna kiselina butil ester;
4-{(R)-2-[(6-ciklopentiloksi-2-fenil-pirimidin-4-karbonil)-amino]-3-fosfono-propionil}-piperazin-1-karboksilna kiselina etil ester;
4-[(S)-2-{[6-((S)-3-metoksi-pirolidin-1-il)-2-fenil-pirimidin-4-karbonil]-amino}-3-(4-fosfono-fenil)-propionil]-piperazin-1-karboksilna kiselina etil ester;
4-[2-{[6-((S)-3-metoksi-pirolidin-1-il)-2-fenil-pirimidin-4-karbonil]-amino}-2-(4-fosfono-fenil)-acetil]-piperazin-1-karboksilna kiselina etil ester;
4-[2-{[6-((S)-3-metoksi-pirolidin-1-il)-2-fenil-pirimidin-4-karbonil]-amino}-2-(4-fosfono-fenil)-acetil]-piperazin-1-karboksilna kiselina butil ester;
4-[2-{[6-((S)-3-metoksi-pirolidin-1-il)-2-fenil-pirimidin-4-karbonil]-amino}-2-(3-fosfono-fenil)-acetil]-piperazin-1-karboksilna kiselina etil ester;
4-[2-{[6-((S)-3-metoksi-pirolidin-1-il)-2-fenil-pirimidin-4-karbonil]-amino}-2-(3-fosfono-fenil)-acetil]-piperazin-1-karboksilna kiselina butil ester;
4-[2-{[6-((S)-3-metoksi-pirolidin-1-il)-2-fenil-pirimidin-4-karbonil]-amino}-2-(2-fosfono-fenil)-acetil]-piperazin-1-karboksilna kiselina butil ester;
4-((R)-2-{[6-(4-metil-piperazin-1-il)-2-fenil-pirimidin-4-karbonil]-amino}-3-fosfono-propionil)-piperazin-1-karboksilna kiselina butil ester;
4-{(R)-2-[(6-morfolin-4-il-2-fenil-pirimidin-4-karbonil)-amino]-3-fosfono-propionil}-piperazin-1-karboksilna kiselina butil ester;
N,N’-bis-(etoksikarbonilmetil)-3-{(S)-[6-((S)-3-metoksi-pirolidin-1-il)-2-fenil-pirimidin-4-karbonil]-amino}-4-okso-4-(4-butoksi-karbonil-piperazin-1-il)-butil-fosfonska kiselina diamid;
4-((R)-3-(bis-acetoksimetoksi-fosforil)-2-{[6-((S)-3-metoksi-pirolidin-1-il)-2-fenil-pirimidin-4-karbonil]-amino}-propionil)-piperazin-1-karboksilna kiselina butil ester;
4-((R)-3-(bis-propioniloksimetoksi-fosforil)-2-{[6-((S)-3-metoksi-pirolidin-1-il)-2-fenil-pirimidin-4-karbonil]-amino}-propionil)-piperazin-1-karboksilna kiselina butil ester;
4-((R)-3-(bis-butiriloksimetoksi-fosforil)-2-{[6-((S)-3-metoksi-pirolidin-1-il)-2-fenil-pirimidin-4-karbonil]-amino}-propionil)-piperazin-1-karboksilna kiselina butil ester;
N,N’-bis-(etoksikarbonilmetil)-2-{(R)-[6-((S)-3-metoksi-pirolidin-1-il)-2-fenil-pirimidin-4-karbon-il]-amino}-3-okso-3-(4-butoksi-karbonil-piperazin-1-il)-propil-fosfonska kiselina diamid;
N,N’-bis-((S)-1-etoksikarboniletil)-2-{(R)-[6-((S)-3-metoksi-pirolidin-1-il)-2-fenil-pirimidin-4-karbon-il]-amino}-3-okso-3-(4-butoksi-karbonil-piperazin-1-il)-propil-fosfonska kiselina diamid;
N,N’-bis-(metoksikarbonilmetil)-2-{(R)-[6-((S)-3-metoksi-pirolidin-1-il)-2-fenil-pirimidin-4-karbonil]-amino}-3-okso-3-(4-butoksi-karbonil-piperazin-1-il)-propil-fosfonska kiselina diamid;
N,N’-bis-((S)-1-metoksikarbonil-2-metil-propil)-2-{(R)-[6-((S)-3-metoksi-pirolidin-
1-il)-2-fenil-pirimidin-4-karbonil]-amino}-3-okso-3-(4-butoksi-karbonil-piperazin-1-il)-propil-fosfonska kiselina diamid;
N,N’-bis-(tert-butiloksikarbonilmetil)-2-{(R)-[6-((S)-3-metoksi-pirolidin-1-il)-2-fenil-pirimidin-4-karbonil]-amino}-3-okso-3-(4-butoksi-karbonil-piperazin-1-il)-propil-fosfonska kiselina diamid;
N,N’-bis-((S)-1-metoksikarbonilpropil)-2-{(R)-[6-((S)-3-metoksi-pirolidin-1-il)-2-fenil-pirimidin-4-karbonil]-amino}-3-okso-3-(4-butoksi-karbonil-piperazin-1-il)-propil-fosfonska kiselina diamid;
N,N’-bis-((S)-1-metoksikarbonil-2,2-dimetil-propil)-2-{(R)-[6-((S)-3-metoksi-pirolidin-1-il)-2-fenil-pirimidin-4-karbonil]-amino}-3-okso-3-(4-butoksi-karbonil-piperazin-1-il)-propil-fosfonska kiselina diamid;
N,N’-bis-((S)-1-tert-butiloksikarboniletil)-2-{(R)-[6-((S)-3-metoksi-pirolidin-1-il)-2-fenil-pirimidin-4-karbonil]-amino}-3-okso-3-(4-butoksi-karbonil-piperazin-1-il)-propil-fosfonska kiselina diamid;
N,N’-bis-((S)-1-metoksikarbonil-2-fenil-etil)-2-{(R)-[6-((S)-3-metoksi-pirolidin-1-il)-2-fenil-pirimidin-4-karbonil]-amino}-3-okso-3-(4-butoksi-karbonil-piperazin-1-il)-propil-fosfonska kiselina diamid;
N,N’-bis-((S)-metoksikarbonilfenilmetil)-2-{(R)-[6-((S)-3-metoksi-pirolidin-1-il)-2-fenil-pirimidin-4-karbonil]-amino}-3-okso-3-(4-butoksi-karbonil-piperazin-1-il)-propil-fosfonska kiselina diamid;
N,N’-bis-((S)-1-metoksikarboniletil)-2-{(R)-[6-((S)-3-metoksi-pirolidin-1-il)-2-fenil-pirimidin-4-karbonil]-amino}-3-okso-3-(4-butoksi-karbonil-piperazin-1-il)-propil-fosfonska kiselina diamid;
N,N’-bis-(propiloksikarbonilmetil)-2-{(R)-[6-((S)-3-metoksi-pirolidin-1-il)-2-fenil-pirimidin-4-karbonil]-amino}-3-okso-3-(4-butoksi-karbonil-piperazin-1-il)-propil-fosfonska kiselina diamid;
N,N’-bis-(izopropiloksikarbonilmetil)-2-{(R)-[6-((S)-3-metoksi-pirolidin-1-il)-2-fenil-pirimidin-4-karbonil]-amino}-3-okso-3-(4-butoksi-karbonil-piperazin-1-il)-propil-fosfonska kiselina diamid;
N,N’-bis-(2-etoksikarbonil-prop-2-il)-2-{(R)-[6-((S)-3-metoksi-pirolidin-1-il)-2-fenil-pirimidin-4-karbonil]-amino}-3-okso-3-(4-butoksi-karbonil-piperazin-1-il)-propil-fosfonska kiselina diamid;
4-((R)-3-(bis-metoksikarboniloksimetoksi-fosforil)-2-{[6-((S)-3-metoksi-pirolidin-1-il)-2-fenil-pirimidin-4-karbonil]-amino}-propionil)-piperazin-1-karboksilna kiselina butil ester;
4-((R)-3-(bis-etoksikarboniloksimetoksi-fosforil)-2-{[6-((S)-3-metoksi-pirolidin-1-il)-2-fenil-pirimidin-4-karbonil]-amino}-propionil)-piperazin-1-karboksilna kiselina butil ester;
4-((R)-3-(bis-izopropoksikarboniloksimetoksi-fosforil)-2-{[6-((S)-3-metoksi-pirolidin-1-il)-2-fenil-pirimidin-4-karbonil]-amino}-propionil)-piperazin-1-karboksilna kiselina butil ester;
4-((R)-3-(bis-tert-butoksikarboniloksimetoksi-fosforil)-2-{[6-((S)-3-metoksi-pirolidin-1-il)-2-fenil-pirimidin-4-karbonil]-amino}-propionil)-piperazin-1-karboksilna kiselina butil ester;
4-((R)-3-[bis-(1-etiloksikarboniloksi-etoksi)-fosforil]-2-{[6-((S)-3-metoksi-pirolidin-1-il)-2-fenil-pirimidin-4-karbonil]-amino}-propionil)-piperazin-1-karboksilna kiselina butil ester;
4-((R)-3-[bis-(1-izopropiloksikarboniloksi-etoksi)-fosforil]-2-{[6-((S)-3-metoksi-pirolidin-1-il)-2-fenil-pirimidin-4-karbonil]-amino}-propionil)-piperazin-1-karboksilna kiselina butil ester;
4-((R)-3-[bis-(1-cikloheksiloksikarboniloksi-etoksi)-fosforil]-2-{[6-((S)-3-metoksi-pirolidin-1-il)-2-fenil-pirimidin-4-karbonil]-amino}-propionil)-piperazin-1-karboksilna kiselina butil ester;
4-((R)-3-(difenoksi-fosforil)-2-{[6-((S)-3-metoksi-pirolidin-1-il)-2-fenil-pirimidin-4-karbonil]-amino}-propionil)-piperazin-1-karboksilna kiselina butil ester;
4-((R)-3-[bis-(5-metil-2-okso-[1,3]dioksol-4-ilmetoksi)-fosforil]-2-{[6-((S)-3-metoksi-pirolidin-1-il)-2-fenil-pirimidin-4-karbonil]-amino}-propionil)-piperazin-1-karboksilna kiselina butil ester;
4-[(R)-2-{[6-((S)-3-metoksi-pirolidin-1-il)-2-fenil-pirimidin-4-karbonil]-amino}-3-(2-okso-4H-2λ5-benzo[1,3,2]dioksafosfinin-2-il)-propionil]-piperazin-1-karboksilna kiselina butil ester;
4-[(R)-2-{[6-((S)-3-metoksi-pirolidin-1-il)-2-fenil-pirimidin-4-karbonil]-amino}-3-(2-okso-1,4-dihidro-2H-2λ5-benzo[d][1,3,2]oksazafosfinin-2-il)-propionil]-piperazin-
1-karboksilna kiselina butil ester;
4-[(R)-2-{[6-((S)-3-metoksi-pirolidin-1-il)-2-fenil-pirimidin-4-karbonil]-amino}-3-(8-metil-2-okso-1,4-dihidro-2H-2λ5-benzo[d][1,3,2]oksazafosfinin-2-il)-propionil]-piperazin-1-karboksilna kiselina butil ester;
4-((R)-3-[bis-(3-okso-1,3-dihidro-izobenzofuran-1-iloksi)-fosforil]-2-{[6-((S)-3-metoksi-pirolidin-1-il)-2-fenil-pirimidin-4-karbonil]-amino}-propionil)-piperazin-1-karboksilna kiselina butil ester;
4-((R)-3-(bis-etoksikarbonilmetoksi-fosforil)-2-{[6-((S)-3-metoksi-pirolidin-1-il)-2-fenil-pirimidin-4-karbonil]-amino}-propionil)-piperazin-1-karboksilna kiselina butil ester;
4-((R)-3-[bis-((S)-1-etoksikarbonil-etoksi)-fosforil]-2-{[6-((S)-3-metoksi-pirolidin-1-il)-2-fenil-pirimidin-4-karbonil]-amino}-propionil)-piperazin-1-karboksilna kiselina butil ester;
N-[(S)-1-etoksikarbonil-etil]-O-fenil-2-{(R)-[6-((S)-3-metoksi-pirolidin-1-il)-2-fenil-pirimidin-4-karbonil]-amino}-3-okso-3-(4-butoksi-karbonil-piperazin-1-il)-propil-fosfonska kiselina amid;
4-[(R)-2-{[6-((S)-3-metoksi-pirolidin-1-il)-2-fenil-pirimidin-4-karbonil]-amino}-3-(2-okso-2λ5-[1,3,2]dioksafosfinan-2-il)-propionil]-piperazin-1-karboksilna kiselina butil ester;
4-[(R)-2-{[6-((S)-3-metoksi-pirolidin-1-il)-2-fenil-pirimidin-4-karbonil]-amino}-3-(8-metil-2-okso-4H-2λ5-benzo[1,3,2]dioksafosfinin-2-il)-propionil]-piperazin-1-karboksilna kiselina butil ester;
4-((R)-3-(8-izopropil-2-okso-4H-2λ5-benzo[1,3,2]dioksafosfinin-2-il)-2-{[6-((S)-3-metoksi-pirolidin-1-il)-2-fenil-pirimidin-4-karbonil]-amino}-propionil)-piperazin-1-karboksilna kiselina butil ester;
4-((R)-3-(8-metoksi-2-okso-1,4-dihidro-2H-2λ5-benzo[d][1,3,2]oksazafosfinin-2-il)-2-{[6-((S)-3-metoksi-pirolidin-1-il)-2-fenil-pirimidin-4-karbonil]-amino)-propionil)-piperazin-1-karboksilna kiselina butil ester;
4-((R)-3-[(5-tert-butil-2-okso-[1,3]dioksol-4-ilmetoksi)-hidroksi-fosforil]-2-{[6-((S)-3-metoksi-pirolidin-1-il)-2-fenil-pirimidin-4-karbonil]-amino}-propionil)-piperazin-1-karboksilna kiselina butil ester;
4-((R)-3-(bis-benziloksi-fosforil)-2-{[6-((S)-3-metoksi-pirolidin-1-il)-2-fenil-pirimidin-4-karbon-il]-amino}-propionil)-piperazin-1-karboksilna kiselina butil ester;
4-((R)-3-(acetoksimetoksi-hidroksi-fosforil)-2-{[6-((S)-3-metoksi-pirolidin-1-il)-2-fenil-pirimidin-4-karbonil]-amino}-propionil)-piperazin-1-karboksilna kiselina butil ester;
4-((S)-3-(bis-acetoksimetoksi-fosforil)-2-{[6-((S)-3-metoksi-pirolidin-1-il)-2-fenil-pirimidin-4-karbonil]-amino}-propionil)-piperazin-1-karboksilna kiselina etil ester;
4-((S)-3-(bis-butiriloksimetoksi-fosforil)-2-{[6-((S)-3-metoksi-pirolidin-1-il)-2-fenil-pirimidin-4-karbonil]-amino}-propionil)-piperazin-1-karboksilna kiselina etil ester;
N,N’-bis-((S)-1-etoksikarboniletil)-2-{(S)-[6-((S)-3-metoksi-pirolidin-1-il)-2-fenil-pirimidin-4-karbonil]-amino}-3-okso-3-(4-etoksi-karbonil-piperazin-1-il)-propil-fosfonska kiselina diamid;
4-((S)-3-(bis-etoksikarboniloksimetoksi-fosforil)-2-{[6-((S)-3-metoksi-pirolidin-1-il)-2-fenil-pirimidin-4-karbonil]-amino}-propionil)-piperazin-1-karboksilna kiselina etil ester;
4-((R)-3-(bis-acetoksimetoksi-fosforil)-2-{[6-((S)-3-metoksi-pirolidin-1-il)-2-fenil-pirimidin-4-karbonil]-amino}-propionil)-piperazin-1-karboksilna kiselina etil ester;
4-((R)-3-(bis-butiriloksimetoksi-fosforil)-2-{[6-((S)-3-metoksi-pirolidin-1-il)-2-fenil-pirimidin-4-karbonil]-amino}-propionil)-piperazin-1-karboksilna kiselina etil ester;
N,N’-bis-((S)-1-etoksikarboniletil)-2-{(R)-[6-((S)-3-metoksi-pirolidin-1-il)-2-fenil-pirimidin-4-karbonil]-amino}-3-okso-3-(4-etoksi-karbonil-piperazin-1-il)-propil-fosfonska kiselina diamid;
4-((R)-3-(bis-etoksi-karboniloksimetoksi-fosforil)-2-{[6-((S)-3-metoksi-pirolidin-1-il)-2-fenil-pirimidin-4-karbonil]-amino}-propionil)-piperazin-1-karboksilna kiselina etil ester;
4-((S)-3-[4-(bis-butiriloksimetoksi-fosforil)-fenil]-2-{[6-((S)-3-metoksi-pirolidin-1-il)-2-fenil-pirimidin-4-karbonil]-amino}-propionil)-piperazin-1-karboksilna kiselina etil ester;
N,N’-bis-((S)-1-etoksikarboniletil)-4-[2-((S)-[6-((S)-3-metoksi-pirolidin-1-il)-2-fenil-pirimidin-4-karbonil]-amino)-3-okso-3-(4-etoksi-karbonil-piperazin-1-il)-propil]-fenil-fosfonska kiselina diamid;
i
4-((S)-3-[4-(bis-etoksikarboniloksimetoksi-fosforil)-fenil]-2-{[6-((S)-3-metoksi-pirolidin-1-il)-2-fenil-pirimidin-4-karbonil]-amino}-propionil)-piperazin-1-karboksilna kiselina etil ester;
ili farmaceutski prihvatljiva sol takvog spoja.
13. Lijek, naznačen time, da sadrži spoj formule I prema bilo kojem zahtjevu od 1 do 12, ili farmaceutski prihvatljivu sol takvog spoja.
14. Farmaceutski sastav, naznačen time, da sadrži najmanje jedan spoj formule I prema bilo kojem zahtjevu od 1 do 12, ili farmaceutski prihvatljivu sol takvog spoja, te jedan ili više farmaceutski prihvatljivih nosača, razrjeđivača ili ekscipijenata.
15. Uporaba spoja formule I prema bilo kojem zahtjevu od 1 do 12, ili farmaceutski prihvatljive soli takvog spoja, naznačena time, da je za proizvodnju lijeka za liječenje okluzivnih vaskularnih poremećaja.
16. Spoj formule I prema bilo kojem zahtjevu od 1 do 12, ili farmaceutski prihvatljiva sol takvog spoja, naznačen(a) time, da se koristi za liječenje okluzivnih vaskularnih poremećaja.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IB2007054850 | 2007-11-29 | ||
PCT/IB2008/055002 WO2009069100A1 (en) | 2007-11-29 | 2008-11-28 | Phosphonic acid derivates and their use as p2y12 receptor antagonists |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20120735T1 true HRP20120735T1 (hr) | 2012-10-31 |
Family
ID=40445499
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20120735AT HRP20120735T1 (hr) | 2007-11-29 | 2012-09-14 | Derivati fosfonske kiseline i njihova uporaba kao antagonista p2y12 receptora |
Country Status (25)
Country | Link |
---|---|
US (1) | US8518912B2 (hr) |
EP (1) | EP2225253B1 (hr) |
JP (1) | JP4729133B2 (hr) |
KR (1) | KR101178319B1 (hr) |
CN (1) | CN101868469B (hr) |
AR (1) | AR069494A1 (hr) |
AU (1) | AU2008331163B2 (hr) |
BR (1) | BRPI0819696B1 (hr) |
CA (1) | CA2706475C (hr) |
CY (1) | CY1113151T1 (hr) |
DK (1) | DK2225253T3 (hr) |
ES (1) | ES2388958T3 (hr) |
HK (1) | HK1148287A1 (hr) |
HR (1) | HRP20120735T1 (hr) |
IL (1) | IL205947A (hr) |
MA (1) | MA31983B1 (hr) |
MX (1) | MX2010005519A (hr) |
MY (1) | MY153749A (hr) |
NZ (1) | NZ586445A (hr) |
PL (1) | PL2225253T3 (hr) |
PT (1) | PT2225253E (hr) |
RU (1) | RU2483072C2 (hr) |
SI (1) | SI2225253T1 (hr) |
TW (1) | TWI361690B (hr) |
WO (1) | WO2009069100A1 (hr) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW200640877A (en) | 2005-04-28 | 2006-12-01 | Actelion Pharmaceuticals Ltd | Pyrimidine derivatives |
AR063258A1 (es) | 2006-10-13 | 2009-01-14 | Actelion Pharmaceuticals Ltd | Derivados de 2-aminocarbonil-piridina, una composicion farmaceutica que los contiene y su uso en la preparacion de un medicamento para el tratamiento de trastornos vasculares oclusivos. |
AR063518A1 (es) | 2006-10-25 | 2009-01-28 | Actelion Pharmaceuticals Ltd | Derivados 2-fenil-6-aminocarbonil-pirimidina; composicion farmaceutica; y su uso para tratar y/o prevenir enfermedades vasculares perifericas viscerales, hepaticas y renales, enfermedades cardiovasculares y enfermedades cerebrovasculares asociados con la agregacion de plaquetas, incluyendo trombosis |
NZ585640A (en) | 2007-11-29 | 2011-03-31 | Boehringer Ingelhelheim Internat Gmbh | Derivatives of 6,7-dihydro-5h-imidazo[1,2-alpha]imidazole-3- carboxylic acid amides |
AR071653A1 (es) * | 2008-04-11 | 2010-07-07 | Actelion Pharmaceuticals Ltd | Derivados 2-fenil-4-ciclopropil-pirimidina |
AR071652A1 (es) * | 2008-04-11 | 2010-07-07 | Actelion Pharmaceuticals Ltd | Derivados 2- fenil-piridina substituidos |
CA2756542C (en) | 2009-04-08 | 2017-08-22 | Actelion Pharmaceuticals Ltd | 6-(3-aza-bicyclo[3.1.0]hex-3-yl)-2-phenyl-pyrimidines |
NZ596388A (en) | 2009-04-22 | 2013-05-31 | Actelion Pharmaceuticals Ltd | Thiazole derivatives and their use as p2y12 receptor antagonists |
EP2750676B1 (en) | 2011-08-30 | 2018-01-10 | University of Utah Research Foundation | Methods and compositions for treating nephrogenic diabetes insipidus |
WO2016029037A1 (en) | 2014-08-21 | 2016-02-25 | Srx Cardio, Llc | Composition and methods of use of small molecules as binding ligands for the modulation of proprotein convertase subtilisin/kexin type 9(pcsk9) protein activity |
WO2017063755A1 (en) | 2015-10-12 | 2017-04-20 | Polyphor Ag | Conformationally constrained macrocyclic compounds |
WO2017063757A1 (en) | 2015-10-12 | 2017-04-20 | Polyphor Ag | Conformationally constrained macrocyclic compounds |
PT3515924T (pt) * | 2016-09-22 | 2022-03-11 | Idorsia Pharmaceuticals Ltd | Formas cristalinas |
CN106831866A (zh) * | 2017-02-09 | 2017-06-13 | 广东赛博科技有限公司 | 一类烷氧噻吩芳基氧化膦p2y12受体拮抗剂及其用途 |
CN106831867A (zh) * | 2017-02-09 | 2017-06-13 | 广东赛博科技有限公司 | 一种腈基噻吩芳基氧化膦p2y12受体拮抗剂及其用途 |
CN106831871A (zh) * | 2017-02-09 | 2017-06-13 | 广东赛博科技有限公司 | 一类硝基噻吩芳基氧化膦p2y12受体拮抗剂及其用途 |
CN106831869A (zh) * | 2017-02-09 | 2017-06-13 | 广东赛博科技有限公司 | 胺基噻吩芳基氧化膦p2y12受体拮抗剂及其用途 |
CN106831868A (zh) * | 2017-02-09 | 2017-06-13 | 广东赛博科技有限公司 | 一种胺基噻吩芳基氧化膦p2y12受体拮抗剂及其用途 |
CN106831870A (zh) * | 2017-02-09 | 2017-06-13 | 广东赛博科技有限公司 | 一类腈基噻吩芳基氧化膦p2y12受体拮抗剂及其用途 |
CN106749408A (zh) * | 2017-02-09 | 2017-05-31 | 广东赛博科技有限公司 | 一种硝基噻吩芳基氧化膦p2y12受体拮抗剂及其用途 |
WO2018167139A1 (en) | 2017-03-15 | 2018-09-20 | Idorsia Pharmaceuticals Ltd | Subcutaneous administration of a p2y12 receptor antagonist |
WO2019101647A1 (en) * | 2017-11-21 | 2019-05-31 | Bayer Aktiengesellschaft | 2-phenylpyrimidine-4-carboxamides as ahr inhibitors |
US11566032B2 (en) | 2020-05-08 | 2023-01-31 | Tonix Pharmaceuticals, Inc. | Radio-protective and chemo-protective substituted thiols |
US20230255987A1 (en) | 2020-07-15 | 2023-08-17 | Idorsia Pharmaceuticals Ltd | Aqueous pharmaceutical composition comprising a p2y12 receptor antagonist |
CN112500354A (zh) * | 2020-12-08 | 2021-03-16 | 烟台凯博医药科技有限公司 | 一种4-氯-6-环丙基嘧啶-5-胺的合成方法 |
CA3223733A1 (en) | 2021-07-13 | 2023-01-19 | Nicole Blumer | A process for the synthesis of 4-((r)-2-{[6-((s)-3-methoxy-pyrrolidin-1-yl)-2-phenyl- pyrimidine-4-carbonyl]-amino}-3-phosphono-propionyl)-piperazine-1 -carboxylic acid butyl ester |
WO2023174810A1 (en) | 2022-03-14 | 2023-09-21 | Idorsia Pharmaceuticals Ltd | A process for the synthesis of ( r)-2-(( tert-butoxycarbonyl)amino)-3-(diethoxyphosphoryl)propanoic acid or of phosphonate derivatives thereof |
Family Cites Families (71)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR1003M (fr) | 1960-03-09 | 1961-12-18 | Erba Carlo Spa | Dérivés d'antibiotiques a base de tétracycline. |
US3338963A (en) | 1960-10-28 | 1967-08-29 | American Cyanamid Co | Tetracycline compounds |
USRE26253E (en) | 1963-05-17 | 1967-08-15 | And z-alkylamino-g-deoxytetracycline | |
US3341585A (en) | 1966-05-06 | 1967-09-12 | American Cyanamid Co | Substituted 7-and/or 9-amino-6-deoxytetracyclines |
US3345410A (en) | 1966-12-01 | 1967-10-03 | American Cyanamid Co | Substituted 7- and/or 9-amino tetracyclines |
US3373196A (en) | 1967-03-21 | 1968-03-12 | American Cyanamid Co | 7-and/or 9-(lower alkyl) amino-5a, 6-anhydrotetracyclines |
US3518306A (en) | 1968-02-19 | 1970-06-30 | American Cyanamid Co | 7- and/or 9-(n-nitrosoalkylamino)-6-demethyl-6-deoxytetracyclines |
US3579579A (en) | 1968-04-18 | 1971-05-18 | American Cyanamid Co | Substituted 7- and/or 9-amino-6-demethyl-6-deoxytetracyclines |
JPS5119757A (ja) | 1974-06-25 | 1976-02-17 | Farmaceutici Italia | Arukirutetorasaikurinjudotainoseizoho |
JPS5373586A (en) | 1976-12-09 | 1978-06-30 | Mitsubishi Chem Ind Ltd | New penicillin derivatives |
IT1135476B (it) | 1981-02-16 | 1986-08-20 | Brionvega Spa | Disposizione per l'orientamento automatico di una antenna in un radioricevitore o televisore per mezzo d'un telecomando |
CA2020437A1 (en) | 1989-07-05 | 1991-01-06 | Yoshihide Fuse | Cinnamamide derivative |
ES2168254T3 (es) | 1991-10-04 | 2002-06-16 | American Cyanamid Co | Nuevas 7-sustituidas-9-(amino sustituido)-6-desmetil-6-desoxitetraciclinas. |
US5494903A (en) | 1991-10-04 | 1996-02-27 | American Cyanamid Company | 7-substituted-9-substituted amino-6-demethyl-6-deoxytetracyclines |
US5281628A (en) | 1991-10-04 | 1994-01-25 | American Cyanamid Company | 9-amino-7-(substituted)-6-demethyl-6-deoxytetracyclines |
US5284963A (en) | 1992-08-13 | 1994-02-08 | American Cyanamid Company | Method of producing 7-(substituted)-9-[(substituted glycyl)-amidol]-6-demethyl-6-deoxytetra-cyclines |
SG47520A1 (en) | 1992-08-13 | 1998-04-17 | American Cyanamid Co | New method for the production of 9-amino-6-demethyl-6-deoxytetracycline |
US5328902A (en) | 1992-08-13 | 1994-07-12 | American Cyanamid Co. | 7-(substituted)-9-[(substituted glycyl)amido]-6-demethyl-6-deoxytetracyclines |
US6693130B2 (en) | 1999-02-18 | 2004-02-17 | Regents Of The University Of California | Inhibitors of epoxide hydrolases for the treatment of hypertension |
US6258822B1 (en) | 1997-08-06 | 2001-07-10 | Abbott Laboratories | Urokinase inhibitors |
AU2466099A (en) | 1998-01-23 | 1999-08-09 | Trustees Of Tufts College | Pharmaceutically active compounds and methods of use thereof |
US7041297B1 (en) | 1998-06-25 | 2006-05-09 | Sumitomo Pharmaceuticals Company | Tumor antigen peptides originating in cyclophilin B |
KR100701635B1 (ko) | 1998-11-18 | 2007-03-30 | 콜라제넥스 파마슈티칼스, 인크 | 신규한 4-데디메틸아미노테트라시클린 유도체 |
WO2000076971A2 (en) | 1999-06-14 | 2000-12-21 | Eli Lilly And Company | Serine protease inhibitors |
US8106225B2 (en) | 1999-09-14 | 2012-01-31 | Trustees Of Tufts College | Methods of preparing substituted tetracyclines with transition metal-based chemistries |
DE60027465T2 (de) | 1999-09-14 | 2007-02-01 | The Trustees Of Tufts College, Medford | Verfahren zur herstellung von substituierten tetracyclinen mit hilfe von auf übergangsmetalle basierten chemien |
JP2003523963A (ja) | 2000-01-24 | 2003-08-12 | トラスティーズ・オブ・タフツ・カレッジ | クリプトスポリジウム・パルヴム関連疾患の治療のためのテトラサイクリン化合物 |
BR0109725A (pt) | 2000-03-31 | 2003-02-04 | Tufts College | Composto de tetraciclina substituìdo, método para tratar um estado responsivo a tetraciclina em um mamìfero, composição farmacêutica, método para sintetizar um composto de tetraciclina 7- ou 9-substituìdo, e, intermediário reativo |
AU2001259701A1 (en) | 2000-05-15 | 2001-11-26 | Paratek Pharmaceuticals, Inc | 7-substituted fused ring tetracycline compounds |
US20020128237A1 (en) | 2000-06-16 | 2002-09-12 | Nelson Mark L. | 7-N-substituted phenyl tetracycline compounds |
US20020132798A1 (en) | 2000-06-16 | 2002-09-19 | Nelson Mark L. | 7-phenyl-substituted tetracycline compounds |
AU2001268475A1 (en) | 2000-06-16 | 2002-01-02 | Trustees Of Tufts College | 7-phenyl-substituted tetracycline compounds |
DE60144375D1 (de) | 2000-07-07 | 2011-05-19 | Trustees Of Tufts College Medford | 7-, 8- und 9-substitutierte tetracyclinverbindungen |
WO2002004406A2 (en) | 2000-07-07 | 2002-01-17 | Trustees Of Tufts College | 9-substituted minocycline compounds |
US7094806B2 (en) | 2000-07-07 | 2006-08-22 | Trustees Of Tufts College | 7, 8 and 9-substituted tetracycline compounds |
US7018985B1 (en) * | 2000-08-21 | 2006-03-28 | Inspire Pharmaceuticals, Inc. | Composition and method for inhibiting platelet aggregation |
US7553828B2 (en) | 2001-03-13 | 2009-06-30 | Paratek Pharmaceuticals, Inc. | 9-aminomethyl substituted minocycline compounds |
CZ20032780A3 (cs) | 2001-03-13 | 2004-01-14 | Paratek Pharmaceuticals, Inc. | 7,9- Substituované tetracyklinové sloučeniny |
AU2002250331A1 (en) | 2001-03-13 | 2002-09-24 | Paratek Pharmaceuticals, Inc. | 7-pyrollyl tetracycline compounds and methods of use thereof |
WO2002072031A2 (en) | 2001-03-14 | 2002-09-19 | Paratek Pharmaceuticals, Inc. | Substituted tetracycline compounds as synergistic antifungal agents |
CA2457234A1 (en) | 2001-03-14 | 2002-09-19 | Mark L. Nelson | Substituted tetracycline compounds as antifungal agents |
US8088820B2 (en) | 2001-04-24 | 2012-01-03 | Paratek Pharmaceuticals, Inc. | Substituted tetracycline compounds for the treatment of malaria |
EP1399414B1 (en) | 2001-04-24 | 2010-01-13 | Paratek Pharmaceuticals, Inc. | Substituted tetracycline compounds for the treatment of malaria |
US6861424B2 (en) | 2001-06-06 | 2005-03-01 | Schering Aktiengesellschaft | Platelet adenosine diphosphate receptor antagonists |
WO2003005971A2 (en) | 2001-07-13 | 2003-01-23 | Paratek Pharmaceuticals, Inc. | Tetracycline compounds having target therapeutic activities |
EP2322501B1 (en) | 2002-01-08 | 2015-08-05 | Paratek Pharmaceuticals, Inc. | 4-dedimethylamino tetracycline compounds |
EP1327903A1 (de) | 2002-01-14 | 2003-07-16 | Alcatel | Optischer Wellenleiterphasenschieber |
KR101093842B1 (ko) | 2002-03-08 | 2011-12-13 | 파라테크 파마슈티컬스, 인크. | 아미노-메틸 치환된 테트라시클린 화합물 |
CN1653037A (zh) | 2002-03-21 | 2005-08-10 | 帕拉特克药品公司 | 取代的四环素化合物 |
BR0313974A (pt) | 2002-09-03 | 2005-07-19 | Solvay Advanced Polymers Llc | Composição de polìmero, artigo fabricado em fusão, artigo extrusado, artigo moldado por injeção, utensìlio de cozinha, método para aumentar a condutividade térmica de um artigo, e, uso de partìculas de metal |
DE10241156A1 (de) | 2002-09-05 | 2004-03-18 | Infineon Technologies Ag | Verfahren zum Herstellen einer integrierten pin-Diode und zugehörige Schaltungsanordnung |
EP2039683B1 (en) * | 2002-10-03 | 2012-12-19 | Targegen, Inc. | Vasculostatic agents and methods of use thereof |
JP4686189B2 (ja) | 2002-10-24 | 2011-05-18 | パラテック ファーマシューティカルズ インコーポレイテッド | Rnaを調節するための置換テトラサイクリン化合物の使用方法 |
US7056923B2 (en) | 2002-12-11 | 2006-06-06 | Schering Aktiengesellschaft | Platelet adenosine diphosphate receptor antagonists |
EP1611144B1 (en) | 2003-04-09 | 2010-09-15 | Wyeth LLC | Derivatives of 2-(8,9-dioxo-2,6-diazabicyclo(5.2.0)non-1(7)-en-2-yl)alkyl phosphonic acid and their use as n-methyl-d-aspartate (nmda) recetor antagonists |
EA201001081A1 (ru) | 2003-07-09 | 2011-02-28 | Пэрэтек Фамэсьютикэлс, Инк. | Соединения тетрациклина, фармацевтическая композиция и способ лечения чувствительного к тетрациклину состояния у субъекта |
EP1656341A1 (en) | 2003-07-09 | 2006-05-17 | Paratek Pharmaceuticals, Inc. | Prodrugs of 9-aminomethyl tetracycline compounds |
US7488739B2 (en) * | 2003-07-24 | 2009-02-10 | Astellas Pharma Inc. | Quinolone derivative or salt thereof |
EP1716101A1 (en) | 2004-01-15 | 2006-11-02 | Paratek Pharmaceuticals, Inc. | Aromatic a-ring derivatives of tetracycline compounds |
TW200640877A (en) * | 2005-04-28 | 2006-12-01 | Actelion Pharmaceuticals Ltd | Pyrimidine derivatives |
EP1940814B1 (en) | 2005-10-21 | 2013-05-22 | Actelion Pharmaceuticals Ltd. | Piperazine derivatives as antimalarial agents |
AR063258A1 (es) | 2006-10-13 | 2009-01-14 | Actelion Pharmaceuticals Ltd | Derivados de 2-aminocarbonil-piridina, una composicion farmaceutica que los contiene y su uso en la preparacion de un medicamento para el tratamiento de trastornos vasculares oclusivos. |
AR063518A1 (es) * | 2006-10-25 | 2009-01-28 | Actelion Pharmaceuticals Ltd | Derivados 2-fenil-6-aminocarbonil-pirimidina; composicion farmaceutica; y su uso para tratar y/o prevenir enfermedades vasculares perifericas viscerales, hepaticas y renales, enfermedades cardiovasculares y enfermedades cerebrovasculares asociados con la agregacion de plaquetas, incluyendo trombosis |
JP4785881B2 (ja) * | 2007-02-27 | 2011-10-05 | 大塚製薬株式会社 | 医薬 |
BRPI0810462A2 (pt) | 2007-04-23 | 2014-10-14 | Sanofi Aventis | Derivados de quinolina-carboxamida como antagonistas de p2y12 |
EP2238127B1 (en) | 2007-12-26 | 2012-08-15 | Sanofi | Pyrazole-carboxamide derivatives as p2y12 antagonists |
WO2009080226A2 (en) | 2007-12-26 | 2009-07-02 | Sanofis-Aventis | Heterocyclic pyrazole-carboxamides as p2y12 antagonists |
AR071653A1 (es) | 2008-04-11 | 2010-07-07 | Actelion Pharmaceuticals Ltd | Derivados 2-fenil-4-ciclopropil-pirimidina |
AR071652A1 (es) | 2008-04-11 | 2010-07-07 | Actelion Pharmaceuticals Ltd | Derivados 2- fenil-piridina substituidos |
CA2756542C (en) | 2009-04-08 | 2017-08-22 | Actelion Pharmaceuticals Ltd | 6-(3-aza-bicyclo[3.1.0]hex-3-yl)-2-phenyl-pyrimidines |
NZ596388A (en) | 2009-04-22 | 2013-05-31 | Actelion Pharmaceuticals Ltd | Thiazole derivatives and their use as p2y12 receptor antagonists |
-
2008
- 2008-11-28 RU RU2010126048/04A patent/RU2483072C2/ru active
- 2008-11-28 CA CA2706475A patent/CA2706475C/en active Active
- 2008-11-28 PT PT08855100T patent/PT2225253E/pt unknown
- 2008-11-28 ES ES08855100T patent/ES2388958T3/es active Active
- 2008-11-28 JP JP2010535498A patent/JP4729133B2/ja active Active
- 2008-11-28 WO PCT/IB2008/055002 patent/WO2009069100A1/en active Application Filing
- 2008-11-28 BR BRPI0819696A patent/BRPI0819696B1/pt active IP Right Grant
- 2008-11-28 MX MX2010005519A patent/MX2010005519A/es active IP Right Grant
- 2008-11-28 CN CN200880116983.8A patent/CN101868469B/zh active Active
- 2008-11-28 SI SI200830722T patent/SI2225253T1/sl unknown
- 2008-11-28 US US12/745,358 patent/US8518912B2/en active Active
- 2008-11-28 KR KR1020107012062A patent/KR101178319B1/ko active IP Right Grant
- 2008-11-28 EP EP08855100A patent/EP2225253B1/en active Active
- 2008-11-28 NZ NZ586445A patent/NZ586445A/en unknown
- 2008-11-28 DK DK08855100.7T patent/DK2225253T3/da active
- 2008-11-28 AU AU2008331163A patent/AU2008331163B2/en active Active
- 2008-11-28 MY MYPI2010002493A patent/MY153749A/en unknown
- 2008-11-28 AR ARP080105205A patent/AR069494A1/es active IP Right Grant
- 2008-11-28 TW TW097146477A patent/TWI361690B/zh active
- 2008-11-28 PL PL08855100T patent/PL2225253T3/pl unknown
-
2010
- 2010-05-25 IL IL205947A patent/IL205947A/en active IP Right Grant
- 2010-06-08 MA MA32897A patent/MA31983B1/fr unknown
-
2011
- 2011-03-07 HK HK11102247.4A patent/HK1148287A1/xx unknown
-
2012
- 2012-09-14 HR HRP20120735AT patent/HRP20120735T1/hr unknown
- 2012-09-27 CY CY20121100884T patent/CY1113151T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20120735T1 (hr) | Derivati fosfonske kiseline i njihova uporaba kao antagonista p2y12 receptora | |
HRP20160002T1 (hr) | Bicikliäśki heterocikliäśki spojevi kao inhibitori protein tirozin kinaze | |
HRP20191027T1 (hr) | Derivati imidazopiridina kao inhibitori tiposinskih receptora kinaza | |
ES2795366T3 (es) | Compuestos de indol carboxamida útiles como inhibidores de cinasas | |
RU2397168C2 (ru) | Производные тиофена в качестве ингибиторов снк 1 | |
HRP20180483T1 (hr) | Spoj kinolona | |
HRP20170393T1 (hr) | Inhibitori c-fms kinaze | |
RS53588B1 (en) | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | |
HRP20211218T1 (hr) | Inhibitori receptora fibroblastnog faktora rasta | |
HRP20130976T1 (hr) | Karbonilaminopirolopirazoli, potentni inhibitori kinaza | |
RU2014141579A (ru) | Гетероциклические соединения в качестве ингибиторов бета-лактамаз | |
ATE463483T1 (de) | 6-substituierte isochinolinderivate als rock-1- inhibitoren | |
NZ627036A (en) | Piperidino-pyrimidine derivatives for the treatment of viral infections | |
MEP43308A (hr) | Derivati cikloalkilamino kisjeline i njihove farmaceutske kompozicije | |
HRP20201107T1 (hr) | Heteroaril amidi kao inhibitori proteinske agregacije | |
AR073551A1 (es) | Pirimidinas macrociclicas como inhibidores de proteina cinasa | |
AR029489A1 (es) | Piridinas, pirimidinas, pirazinas, triazinas sustituidas por arilo, composiciones farmaceuticas y el uso de las mismas para la manufactura de un medicamento | |
HRP20100670T1 (hr) | Aril-supstituirani pirazol-amid spojevi korisni kao inhibitori kinaze | |
HRP20110841T1 (hr) | Korisni monobaktamski antibiotici | |
HRP20201400T1 (hr) | Spojevi 6-aril-4-(morfolin-4-il)-1h-piridin-2-ona korisni za liječenje karcinoma i dijabetesa | |
HRP20220479T1 (hr) | Spojevi | |
SI3102573T1 (en) | SUBSTITUTED TIAZOL OR OXASOL AS ANTAGONISTS OF THE RECEPTOR P2X7 | |
HRP20110344T1 (hr) | Derivati dihidropiridina | |
HRP20110938T1 (hr) | Spojevi koji sadrže gvanidin i koji se koriste kao agonisti muskarinskih receptora | |
HRP20201932T1 (hr) | Stimulatori / aktivatori topive gvanilat-ciklaze u kombinaciji s nep-inhibitorom i/ili angiotenzin aii-antagonistom i njihova uporaba |